epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

Evidence library

References

Where each of epiClinical's numbers comes from, and every work the evidence review drew on, chapter by chapter.

Where each number comes from

Evidence-anchored Direction from evidence Illustrative

Therapeutic-area baselines (6)
NumberValueSource
Oncology 0.35 patients per site per monthInside published ranges: IQVIA medians 0.1 to 0.2, industry Phase III mean 0.80 in oncology (D01)
Cardiovascular 0.3 patients per site per monthCV trials analysis (Khan et al. 2025, JAMA Cardiology): 0.3 patients/site/month overall, US 0.2
CNS and psychiatry 0.45 patients per site per monthNo per-site rate by therapeutic area was found; value sits inside the all-area range (D01)
Immunology and GI 0.3 patients per site per monthNo per-site rate by therapeutic area was found; value sits inside the all-area range (D01)
Respiratory 0.4 patients per site per monthNo per-site rate by therapeutic area was found; value sits inside the all-area range (D01)
Rare disease 0.1 patients per site per monthRare-disease trials recruit far fewer patients per site; value sits inside published ranges (D01)
Country multipliers (6)
NumberValueSource
United States ×0.75Site-productivity index: US sites yield 0.76 to 0.77 of the study average (D03). Khan et al. found 0.2 against 0.3 overall in cardiovascular trials; in oncology IQVIA reports US sites ahead of European ones
United Kingdom ×0.85Site-productivity index (D04). The UK is the only country with measured public-trial rates (0.92 to 0.95 per centre per month); commercial recruitment fell 44% from 2017/18 to 2021/22
Spain ×1Spanish sites yield 75 to 90% of the study average and IQVIA's oncology median matches the UK and Germany (D05). Spain's real advantage is start-up speed: 231 days from submission to first dose (2022) (INFARMA 2021)
Poland ×1.4Site-productivity index: Polish sites yield 148 to 167% of the study average (D06); growth has stalled since 2022
Turkey ×1No current per-site rate exists (D08). The only index (2006 to 2008) put Turkey at 0.70 of average, and IQVIA's recruitment score ranks it below Poland and Spain
India ×1.1India matched the US per site in FDA's FY2008 inspections and reached about 17 per site against Poland's 22 in EMA 2005 to 2009 data, which implies about ×1.08 (D07; range 1.0 to 1.3)
Site multipliers (17)
NumberValueSource
Site type: Academic hospital ×1Reference category
Site type: Dedicated research centre ×1.25Research-focused sites recruited 41% better in a 72-protocol analysis; range 1.2 to 1.3 (D10)
Site type: Community hospital ×0.85UK GP sites 0.52 to 0.71 against hospital 0.90 to 1.22 per centre per month2; US community enrolment 7.0% of patients against 15.9% at academic centres (D10)
Site type: Private practice ×0.75Independent practices recruit below hospital sites; range 0.7 to 0.75 (D10)
Track record: Average ×1Reference category
Track record: Top-quartile enroller ×1.4A site's record predicts its next trial only weakly (correlation 0.13 to 0.16, up to 0.46 with patient-volume data), so the selection effect is smaller than the spread of outcomes (D11)
Track record: New site, no history ×0.75epiClinical assumption
Track record: Previously under-enrolled ×0.5Past enrolment predicts future enrolment weakly; plausible range 0.5 to 0.6 (D11)
Protocol & population: Standard ×1Reference category
Protocol & population: Second line ×0.6Real-world attrition between treatment lines is 40 to 60% in lung cancer23 (D14)
Protocol & population: Third line or later ×0.4Attrition compounds at each line, so the eligible pool shrinks faster than one rate ratio implies (D14)
Protocol & population: Rare orphan population ×0.73Accrual in trials behind FDA cancer approvals (2024): Poisson adjusted rate ratio 0.73 against non-orphan. Never combined with the rare-disease baseline (D16)
Competing trials: A few ×1Reference category
Competing trials: None ×1.1epiClinical assumption
Competing trials: Heavy competition ×0.75Applies when the eligible pool is scarce: low-accrual odds rose 1.88 times per extra competing trial per 10,000 eligible patients a year (787 NCI trials); no effect when patients were plentiful (D12)
Protocol & population: Moderately restrictive eligibility ×0.8One or two non-essential exclusions. Three common lung-cancer exclusions cut the eligible pool from 98.5% to 52.3% (Harvey 2021) (D13)
Protocol & population: Highly restrictive eligibility ×0.55Three or more non-essential exclusions; more criteria independently predict accrual failure (Carlisle 2015) (D13)
Planner parameters (34)
NumberValueSource
Site-to-site variation 1 coefficient of variationFitted gamma shapes of 1.2 to 2.3 in real trials (Minois et al. 2017; Bakhshi 2011, median shape 1.43); Anisimov's planning examples use 1.2
Site-to-site variation, lower 1 coefficient of variationIFM myeloma trials, gamma shape 1.75 to 2.15 (Minois et al., Statistics in Medicine 2017)
Site-to-site variation, upper 1 coefficient of variationAnisimov and Austin 2022: the 'medium variation' planning setting
First site opens, United States 4 monthsFirst US site activated a median 124 days after final protocol approval (Friends of Cancer Research, pivotal oncology trials 2020 to 2025)
Last site opens, United States 10 monthsUS took 309 days to activate 75% of planned sites (Friends of Cancer Research 2026)
First site opens, United Kingdom 4 monthsMedian 122 days from application to first participant, commercial CTIMPs, April to September 2025 (UK clinical research delivery KPIs)
Last site opens, United Kingdom 10 monthsepiClinical assumption: sites open over six months after the first
First site opens, Spain 8 monthsMedian 231 days from submission to first dose, 2022 (IQVIA for EFPIA 2024)
Last site opens, Spain 14 monthsepiClinical assumption: sites open over six months after the first
First site opens, Poland 11 monthsEEA oncology site start-up averages 339 days (IQVIA for EFPIA 2024); no Poland-specific median found
Last site opens, Poland 17 monthsepiClinical assumption: sites open over six months after the first
First site opens, Turkey 6 monthsNo median found; statutory clocks are 12 business days for ethics and 22 for TİTCK, plus contracting
Last site opens, Turkey 12 monthsepiClinical assumption: sites open over six months after the first
First site opens, India 6 monthsStatutory chain: CDSCO 90 working days with ethics review in parallel, a 5 to 6 month planning assumption (NDCT Rules 2019)
Last site opens, India 12 monthsepiClinical assumption: sites open over six months after the first
Most sites a country can supply, United States 100 sites1,500 × share of global active industry sites (32.1%, LongTaal 2024), capped at 100; the scale is an assumption chosen so the portfolio studies fit
Most sites a country can supply, United Kingdom 44 sites1,500 × share of global active industry sites (2.9%, LongTaal 2024); the scale is an assumption chosen so the portfolio studies fit
Most sites a country can supply, Spain 71 sites1,500 × share of global active industry sites (4.7%, LongTaal 2024); the scale is an assumption chosen so the portfolio studies fit
Most sites a country can supply, Poland 41 sites1,500 × share of global active industry sites (2.7%, LongTaal 2024); the scale is an assumption chosen so the portfolio studies fit
Most sites a country can supply, Turkey 18 sites1,500 × share of global active industry sites (1.2%, LongTaal 2024); the scale is an assumption chosen so the portfolio studies fit
Most sites a country can supply, India 15 sites1,500 × share of global active industry sites (1%, LongTaal 2024); the scale is an assumption chosen so the portfolio studies fit
Sites per country, by default 6 sitesMedian 64 sites per industry Phase III trial (PLOS ONE 2022) across about 11 countries (Tufts CSDD 2012)
Screen failure, overall 36.3%Tufts CSDD 2019: 76 Phase II and III trials completed 2016 to 2019
Screen failure, Oncology 40%34% across 269 trials (UCSD 2013 to 2021) and 51% across 15 RCTs (Tata Memorial 2023)
Screen failure, Cardiovascular 45%Heart failure outcome trials: DAPA-HF 42%, EMPEROR-Reduced 48%
Screen failure, CNS and psychiatry 57%Tufts CSDD 2019: CNS screen failure 57%
Screen failure, Immunology and GI 48%Inflammatory bowel disease trials: ulcerative colitis 43%, Crohn's disease 53% (17 trials, 16,913 screened, 2025)
Screen failure, Respiratory 40%COPD Phase III trials: 37% to 42% screened but not randomised
Screen failure, Rare disease 56%Tufts CSDD 2019: 56% of rare-disease volunteers not randomised
Drop-out 15%Median 11% across 10,252 Phase III trials (Chen et al. 2025) to 19.1% (Tufts CSDD 2019)
Drop-out, CNS and psychiatry 25.9%Tufts CSDD 2019: CNS drop-out 25.9%
Confidence wanted, by default 85%JMP Clinical's default; 0.8 and 0.9 are the common alternatives (Anisimov and Austin 2022)
Uncertainty in the rates themselves 0 coefficient of variationepiClinical assumption: the mean rate is itself an estimate; without this, bands are too narrow (Mountain and Sherlock 2022)
Simulated studies per forecast 10,000 simulated studies10,000 runs as in JMP Clinical and Anisimov and Oliver 2024
Monitoring rules (22)
NumberValueSource
Inner funnel limit: outside it is worth watching 1 two-sided confidenceFunnel plots for comparing institutional performance use 95% and 99.8% limits, roughly two and three standard deviations (Spiegelhalter 2005, Statistics in Medicine)
Outer funnel limit: outside it is an alarm 1 two-sided confidenceFunnel plots for comparing institutional performance use 95% and 99.8% limits, roughly two and three standard deviations (Spiegelhalter 2005, Statistics in Medicine)
Nothing randomised although at least this many patients were expected 3 patients expectedepiClinical assumption: a simple operational trigger of the kind CROs use to start a conversation with a site. With typical site-to-site spread, about one ordinary site in five with three patients expected still has none, so it prompts a call, not a judgement
A study whose first patient comes this many months after its first site opened is flagged 2 monthsTrials slower than 70 days to first patient became slow accruers 23% of the time against 5% (MD Anderson, 4,269 trials); NCI trials whose first patient came after two months were less likely to reach minimum accrual. Both cut-offs come from splitting historical data, not a validated standard (review note 02)
A site is overdue for its first patient when fewer than this share of similar sites would still be waiting 10%epiClinical assumption, using the planner model: each site waits according to its own expected rate and the spread of site rates (coefficient of variation 0.9)
Sites active as a share of plan, below which activation is flagged 80%epiClinical assumption; trials with too few sites are more likely to fail on accrual (review note 02)
Enrolment as a share of the expected count, below which it is flagged 80%epiClinical assumption
Enrolment as a share of the expected count, below which it is outside the acceptable range 60%NCI trials under 60% of target at the planned end rarely recovered (odds ratio 0.19; review note 02)
Planned sites as a share of the countries' site caps, above which the plan is stretched 80%epiClinical assumption; plans needing a large share of the available pool are more likely to under-accrue (Bennette, review note 02)
Patients needed before a QTL is judged 50 patientsepiClinical assumption: QTL rates are unstable with few patients, and many early breaches in vendor data were noise (review note 01)
A site that has recruited below this share of its expected count is behind 75%epiClinical assumption, between the enrolment flag (0.8) and the point NCI trials rarely recovered from (0.6); about half of sites fall short of plan in practice (11% enrol nobody, 37% under-enrol; Tufts, register S-01)
A site that has recruited above this share of its expected count is ahead 125%epiClinical assumption, set symmetrically to the behind line on a ratio scale (1 ÷ 0.8)
Patients a site must have been expected to recruit before it is judged 2 patients expectedepiClinical assumption: below this, a site's count says more about chance than about the site
Patients offered a trial who agree to take part 55%55.0% of patients offered a cancer treatment trial agreed, across 35 studies (Unger 2021, JNCI, https://doi.org/10.1093/jnci/djaa155)
Patients needed at a funnel stage before a site's rate there is compared with the study's 8 patientsepiClinical assumption: with fewer, a single patient moves the rate by more than ten points
A site's rate at a funnel stage is out of line when so poor a rate would happen by chance less often than this 10%epiClinical assumption: a loose screen, because it prompts a look at the screening log rather than a judgement
Power each study is assumed to be designed for 80%Conventional design value; the fictional studies do not state their power
Two-sided significance level each study is assumed to use 5%Conventional design value; the fictional studies do not state it
Power below which a QTL breach is critical and escalated to the sponsor 70%epiClinical assumption: a study designed for 80% power that falls to 70% has lost a third of its margin against a false negative
A study whose forecast finish is this many months past the sponsor’s deadline is red; any slip past the deadline is amber 6 monthsepiClinical assumption: any forecast past the deadline needs a recovery plan, and six months late needs the sponsor’s decision on scope or timelines
Share of sites with data over at least one KRI threshold at which a study is amber 10%epiClinical assumption, to be tuned against which flagged sites went on to need a triggered visit
Share of sites with data over at least one KRI threshold at which a study is red 20%epiClinical assumption, as for the amber share
Key risk indicators (8)
NumberValueSource
Site activation overdue Over 30 daysepiClinical assumption: a month's grace before a late site is escalated
Screen failure above the study's Over +15 pointsepiClinical assumption; screen failure varies widely by therapeutic area (register PM-05), so sites are compared with their own study
Data entry lag Over 7 daysCommon sponsor convention of five working days; no sourced difference between the study countries was found, so every country uses the default
Queries open over 30 days Over 20%epiClinical assumption; TransCelerate lists query ageing among indicators of site data quality, without a standard limit
Important protocol deviations Over 2epiClinical assumption; complex protocols and new sites produce more deviations (register S-24, S-05)
Consent findings Over 5epiClinical assumption; consent documents grow longer and harder to complete (register PD-16)
Study drug at the site Under 4 weeksepiClinical assumption; read from the randomisation and supply system, which the synthetic data does not include
Enrolment against the diversity plan Under 80%FDORA 2022 introduced diversity action plans for Phase III studies in the US, though FDA's guidance on them has been in flux since 2025; racial and ethnic groups are under-represented in US trials (register PB-12). The 80% line is an epiClinical assumption
Quality tolerance limits (12)
NumberValueSource
Missing primary endpoint data Grade AMissing outcome data can overturn up to a third of significant results (Akl 2012); losses exceeded the fragility index in 53% of 399 trials (Walsh 2014)
Missing primary endpoint data: benchmark 7.9%TransCelerate QTL benchmark survey: median 7.9% across sponsors (review note 01)
Missing primary endpoint data: limit The study's drop-out assumptionThe acceptable range is the drop-out the study's power calculation allowed for (planner parameters, D24); the early-warning line sits at two-thirds of it
Lost to follow-up or withdrew consent Grade AThe same missing-data mechanism as missing endpoint data, held tighter than treatment discontinuation (review note 01)
Lost to follow-up or withdrew consent: benchmark 3.7%TransCelerate medians: 0.8% lost to follow-up and 2.9% withdrawal of consent (review note 01)
Lost to follow-up or withdrew consent: limit 6%epiClinical assumption: above the combined benchmark median of 3.7% and in line with published case studies that set limits around 4% for unknown survival status
Stopped study treatment early Grade BThe most widely reported QTL parameter; no study links it directly to trial failure (review note 01) (Makowski 2021)
Stopped study treatment early: benchmark 10.7%TransCelerate median 10.7%; Phase III 11.5% (review note 01)
Stopped study treatment early: limit 15%epiClinical assumption: above the Phase III benchmark of 11.5%; a breach dilutes the treatment effect and reduces power
Ineligible patients randomised Grade BThe most common randomisation error; it dilutes the effect in the intended population (review note 01) (Yelland 2018)
Ineligible patients randomised: benchmark 3.2%TransCelerate median 3.2% (review note 01)
Ineligible patients randomised: limit 5%epiClinical assumption: above the 3.2% median; eligibility errors were reported in 39% of 82 trials
Shock multipliers (30)
NumberValueSource
Pandemic peak (April 2020), United States ×0.55New patients per site 45% below the 2019 baseline in April 2020, read from Medidata’s chart; the same release’s year-on-year table says −83%, so the size is less certain than the UK and India figures (Medidata Release 9.0; D37).
Pandemic peak (April 2020), United Kingdom ×0.13Medidata COVID-19 analyses (2020): new patients per site vs pre-COVID baseline: UK −87% in April
Pandemic peak (April 2020), Spain ×0.4New patients per site 60% below the 2019 baseline in April 2020, read from Medidata’s chart; the year-on-year table says −82% (Medidata Release 9.0; D37).
Pandemic peak (April 2020), Poland ×0.4epiClinical assumption for the peak
Pandemic peak (April 2020), Turkey ×0.35epiClinical assumption for the peak
Pandemic peak (April 2020), India ×0.02Medidata COVID-19 analyses (2020): new patients per site vs pre-COVID baseline: India −98% in April
Pandemic recovery (August 2020), United States ×0.78New patients per site 22% below the 2019 baseline in August 2020, read from Medidata’s chart (Medidata Release 9.0; D37).
Pandemic recovery (August 2020), United Kingdom ×0.6Medidata COVID-19 analyses (2020): new patients per site vs pre-COVID baseline: UK −40% in August
Pandemic recovery (August 2020), Spain ×0.65epiClinical assumption for recovery: two readings of Medidata’s August figure for Spain disagree (+25% and −34%), so it cannot be anchored yet (D37).
Pandemic recovery (August 2020), Poland ×0.7epiClinical assumption for recovery
Pandemic recovery (August 2020), Turkey ×0.65epiClinical assumption for recovery
Pandemic recovery (August 2020), India ×0.29Medidata COVID-19 analyses (2020): new patients per site vs pre-COVID baseline: India −71% in August
Border conflict: site near the border, United States ×1Not affected by this scenario
Border conflict: site near the border, United Kingdom ×1Not affected by this scenario
Border conflict: site near the border, Spain ×1Not affected by this scenario
Border conflict: site near the border, Poland ×1Not affected by this scenario
Border conflict: site near the border, Turkey ×0.3Sites near a conflict border lose most of their patient flow. The direction is supported by Ukraine, where effects concentrated in the east and north; the size is an assumption (Clinical Research News 2022; D39).
Border conflict: site near the border, India ×1Not affected by this scenario
Border conflict: site elsewhere in country, United States ×1Not affected by this scenario
Border conflict: site elsewhere in country, United Kingdom ×1Not affected by this scenario
Border conflict: site elsewhere in country, Spain ×1Not affected by this scenario
Border conflict: site elsewhere in country, Poland ×1Not affected by this scenario
Border conflict: site elsewhere in country, Turkey ×0.9The same conflict barely touches distant sites: about half of Ukraine’s sites kept recruiting. The direction is supported; the size is an assumption (Phesi 2022; D39).
Border conflict: site elsewhere in country, India ×1Not affected by this scenario
Regional war next door (2022 analogue), United States ×1Not affected by this scenario
Regional war next door (2022 analogue), United Kingdom ×1Not affected by this scenario
Regional war next door (2022 analogue), Spain ×1Not affected by this scenario
Regional war next door (2022 analogue), Poland ×1.1The sign is supported: Poland’s recruiting sites rose 10% in 2022 while Ukraine’s fell 48% (Phesi via Lab News 2022). The size is an assumption, and no gain in trials or in each site’s productivity was measured (D38).
Regional war next door (2022 analogue), Turkey ×1Not affected by this scenario
Regional war next door (2022 analogue), India ×1Not affected by this scenario
Shock profiles (27)
NumberValueSource
Pandemic wave: depth (a lower rate at the sites that stay open) 65%New patients per site fell 65% worldwide; in April 2020 the fall was 41% in oncology, 65% in CNS, 92% in respiratory and 97% in cardiovascular trials. Areas without a figure take the overall 65% (Medidata Release 9.0; D30).
Pandemic wave: sites in reach From the study's sitesEvery country in Medidata’s series was hit, so every site is in reach (Medidata Release 6.0; D30).
Pandemic wave: timing 2 months, 5 to recoverTwo months at the bottom and five to recover in Medidata’s global series. Industry protocols were still 31% to 66% down by area in 2021 and the UK regained 2019 levels only in September 2021, hence the long-tail option of 12 to 18 months, drawn at 15 (Medidata Release 9.0; McDonald et al. 2022; D30).
Regional war: depth (recruiting sites lost) 48%Ukraine had 48% fewer recruiting sites seven months into the war and 62% fewer at 13 months, with no recovery (Phesi via Lab News 2022 and 2023; D31).
Regional war: sites in reach From the study's sitesEvery site the study has in the country at war is in reach; the share comes from the study’s own site list (D31, D36).
Regional war: timing 13 months, 30 to recoverThirteen months or more at the bottom and 24 to 36 to recover, drawn at 30: sponsors stayed away for about three years (Clinical Leader 2026; D31).
Border conflict: depth (a lower rate, steepest at the sites near the border) 70%A fall of 70% near the border and 10% elsewhere in the country, with up to a third of enrolled participants near the border lost to follow-up. The gradient is supported, since about half of Ukraine’s sites kept recruiting while effects concentrated in the east and north; the sizes are assumptions (Phesi 2022; Clinical Research News 2022; D32, D39).
Border conflict: sites in reach From the study's sitesThe sites near the border come from the study’s own site list (D32, D36).
Border conflict: timing 6 months, 6 to recoverSix months at the bottom and six to recover are epiClinical assumptions (D32).
Public funding cut: depth (staff and capacity lost at the sites hit) 20%An industry study is hit second-hand, through its academic sites: sites hit by NIH cuts froze hiring (32%) and cut staff (25%) (WCG 2025; D33). The loss of capacity is an assumption. For a publicly funded trial the direct risk was measured: 3.5% of NIH-funded trials lost funding (383 of 11,008), 14.4% in infectious disease, with more than 74,000 participants affected (Patel et al. 2025).
Public funding cut: sites in reach 46%In a survey of 611 sites in 2025, 46% had been hit by NIH cuts or industry trial pauses, larger sites far more often (WCG 2025; D33).
Public funding cut: timing 36 months, 0 to recoverUntil grants are restored or trials close; how long that takes is not measured (D33).
Protocol amendment: depth (a slower rate while the amendment is put in place, and later openings for sites not yet open) 10%Amended protocols recruit for longer and enrol fewer patients than planned, but no study measured the fall in rate; 10% is an epiClinical assumption (Getz 2016; D34).
Protocol amendment: sites in reach From the study's sitesEvery site takes the amendment; 57% to 76% of protocols have at least one (Getz 2016; Getz 2024; D34).
Protocol amendment: timing 9 months, 0 to recoverAbout 260 days to put a substantial amendment in place (Getz 2024; D34).
Seasonality: depth (a rate that dips at the holidays) 10%Recruitment dips by about a tenth in December and January and in July and August; the other months are set so the year averages out (Haidich and Ioannidis 2001; Webster et al. 2015; D34).
Seasonality: sites in reach From the study's sitesEvery site follows the same calendar (D34).
Seasonality: timing 0 months, 0 to recoverThe pattern repeats every year (D34).
Regulatory shock: depth (new approvals and running trials held while the rules change) 71%After India’s Supreme Court ruling, trial approvals fell from 253 in 2012 to 73 in 2013, a fall of 71% (Nair 2015; D34).
Regulatory shock: sites in reach From the study's sitesEvery site in the country is in reach: the ruling held approved trials as well as new ones (Nair 2015; D34).
Regulatory shock: timing 12 months, 12 to recoverAbout a year for the new rules to take hold is an epiClinical reading of the India case; the recovery is an assumption (D34, D43).
Drug shortage: depth (a lower rate at the sites short of the drug) 50%How far enrolment fell at the centres that cut it is not measured; half is an epiClinical assumption (D34).
Drug shortage: sites in reach 58%In 2023, 174 of 608 NCI trials were flagged as hit by cancer drug shortages, and 58% of affected centres reduced enrolment (CNN 2023; The ASCO Post 2024; D34).
Drug shortage: timing 6 months, 6 to recoverSix months short and six to recover are epiClinical assumptions; shortages in the survey lasted months (The ASCO Post 2024; D34).
Earthquake: depth (sites in the disaster zone stop recruiting) 90%Sites in the provinces hit lose almost all their patient flow while hospitals are damaged or overwhelmed; the size is an assumption, the direction is not (IFRC 2023; D34).
Earthquake: sites in reach From the study's sitesThe sites in the provinces hit by the 2023 earthquakes come from the study’s own site list; the regulator’s response, letting patients move to other sites and visits happen remotely, is the playbook to follow (TİTCK 2023; D34).
Earthquake: timing 2 months, 6 to recoverTwo months stopped and six to recover are epiClinical assumptions (D34, D45).
Rescue sites (7)
NumberValueSource
Rescue is called when enrolment falls below this share of plan at a quarterly milestone 0.6Trials below 60% of their target rarely recovered, and an early decision is what makes a rescue work (Cheng 2011; Schroen 2010; D20).
A rescue site recruits at this share of the study’s own sites in the country 0.6Between 0.5 and 0.75 of the base rate; sites added more than about five months after the first patient contribute little, and late starters supplied under 10% of enrolment in 11 of 14 large trials (Li (Phesi) 2018; Haidich and Ioannidis 2003; Tufts CSDD 2013; Phesi 2023; D20).
Share of rescue sites that recruit nobody 0.19Between 11% and 27% of added sites enrolled nobody; the midpoint is used (Li (Phesi) 2018; Tufts CSDD 2013; D20).
Months from opening to full rate: none in the first month, full by the third 3A new site’s first month was assumed empty in the STAR pilot, good independent sites screened a first patient a median 20 days after activation, and 61% of UK studies recruited within 30 days of opening (Bertram 2019; CRIO 2026; UK KPIs 2026; D20).
Months from deciding to add a site to its opening: United States, independent site 4.4US independent sites activated in a median 4.4 months (Smith (WCG) 2024; D20).
Months from deciding to add a site to its opening: United States, academic or hospital site 8.1US academic and hospital sites activated in a median 8.1 months (Smith (WCG) 2024; D20).
Months from deciding to add a site to its opening: United Kingdom 4A median 122 days from application to first participant, 2025 cohort (UK KPIs 2026; D20).
Early-warning settings (6)
NumberValueSource
Tailwind factor 0One measured case: Poland’s recruiting sites rose 10% while Ukraine’s fell 48% (Phesi via Lab News 2022; D41).
Watch threshold 30No published calibration exists; to be tuned by a backtest against Medidata’s monthly series that reports lead time against false alarms (Medidata Releases 2.0 and 9.02; D42).
Act threshold 60No published calibration exists; to be tuned by the same backtest (Medidata Releases 2.0 and 9.02; D42).
Impact visible below 80A convenient rule that the UK met in the first month of the pandemic, when new patients fell more than 20% below 2019 in March 2020 (Medidata Release 2.0; D42).
Lost sales per day of delay, low 500,000The median across medicines (Smith, DiMasi and Getz 2024; D47).
Lost sales per day of delay, high 800,000The Tufts white paper’s estimate (Smith, DiMasi and Getz, white paper 2024; D47).
News categories (16)
NumberValueSource
Public health: half-life 60 daysThe pandemic’s hit to new patients per site halved in about two months (Medidata Release 9.0; D40).
Public health: proximity weights 1, 0.9, 0.7, 0.5Distance barely weakens the signal: WHO’s global declarations came weeks before recruitment collapsed country by country (WHO 2020; Medidata Release 2.0; D41).
Conflict & security: half-life 365 daysUkraine’s recruiting sites were 48% down at seven months and 62% down at 13 months, with no recovery (Phesi via Lab News 2022 and 20232; D40).
Conflict & security: proximity weights 1, 0.5, 0.2, 0The effect falls steeply with distance, and next door it can be a gain: Poland’s recruiting sites rose 10% (Clinical Research News 2022; Phesi via Lab News 2022; D41).
Natural disaster: half-life 60 daysNo study measured how quickly recruitment recovers after a disaster; 60 days is an epiClinical assumption.
Natural disaster: proximity weights 1, 0.3, 0.1, 0The damage is local: hospitals near the epicentre were lost while those further away kept working (IFRC 2023; D41).
Health system capacity: half-life 21 daysStrikes and cyberattacks fade in two to four weeks: hospital activity dipped on strike days and recovered after them (Wyatt et al. 2026; Borchert et al. 2025; D40).
Health system capacity: proximity weights 1, 0.8, 0, 0A strike reaches the sites of the health system on strike, and no further; the weights are epiClinical assumptions.
Policy & funding: half-life 365 daysFunding cuts and new laws act for a year or more, and a law counts from the day it takes effect, however old the news (D40, D43).
Policy & funding: proximity weights 1, 0.8, 0, 0A national law or funder reaches that country’s sites; the weights are epiClinical assumptions.
Regulatory: half-life 365 daysA regulator’s or court’s rule stays live from publication until it takes effect, then fades over a year or more (D40, D43).
Regulatory: proximity weights 1, 0.9, 0, 0A national rule applies to every site in the country; the weights are epiClinical assumptions.
Trust & access: half-life 365 daysMistrust is a slow headwind: the effect of the Tuskegee study on Black men’s use of care lasted decades (Alsan and Wanamaker 2018; D43).
Trust & access: proximity weights 1, 0.6, 0, 0The weights are epiClinical assumptions.
Population movement: half-life 60 daysPeople who move need continuity of care, not a change to the forecast, so these events carry no score; the half-life is an epiClinical assumption.
Population movement: proximity weights 1, 0.8, 0.4, 0The weights are epiClinical assumptions.

The works, chapter by chapter

Each work is listed once, under the first chapter that cites it. 253 of the 768 are cited on this site and marked "Cited here".

Chapter 1 How often recruitment fails, and which statistics to trust

  1. Advarra (formerly Forte Research). Retention in clinical trials: keeping patients on protocols (infographic; data from Clinical Performance Partners and Phesi 1998-2012 and CISCRP surveys).advarra.comRead: full textCited here
  2. Bennette CS, Ramsey SD, McDermott CL, et al. Predicting low accrual in the National Cancer Institute's Cooperative Group clinical trials. Journal of the National Cancer Institute. 2016.doi.orgRead: full textAlso in chapter 3, review note 02Cited here
  3. Bertram W, Moore A, Wylde V, Gooberman-Hill R. Optimising recruitment into trials using an internal pilot. Trials. 2019.pmc.ncbi.nlm.nih.govRead: full textAlso in chapter 3Cited here
  4. Bogin V. Lasagna's law: a dish best served early. Contemporary Clinical Trials Communications. 2022.pmc.ncbi.nlm.nih.govRead: full textCited here
  5. Briel M, Olu KK, von Elm E, et al. A systematic review of discontinued trials suggested that most reasons for recruitment failure were preventable. Journal of Clinical Epidemiology. 2016.doi.orgRead: abstractCited here
  6. Brøgger-Mikkelsen M, Ali Z, Zibert JR, Andersen AD, Thomsen SF. Online patient recruitment in clinical trials: systematic review and meta-analysis. Journal of Medical Internet Research. 2020.doi.orgRead: full text
  7. Brøgger-Mikkelsen M, Zibert JR, Andersen AD, et al. Changes in key recruitment performance metrics from 2008-2019 in industry-sponsored phase III clinical trials registered at ClinicalTrials.gov. PLoS ONE. 2022.doi.orgRead: full text
  8. Campbell MK, Snowdon C, Francis D, et al. Recruitment to randomised trials: strategies for trial enrolment and participation study. The STEPS study. Health Technology Assessment. 2007.doi.orgRead: abstract
  9. Carlisle B, Kimmelman J, Ramsay T, MacKinnon N. Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials. Clinical Trials. 2015.doi.orgRead: full textAlso in chapter 2, chapter 3, review note 01, review note 02Cited here
  10. Chaudhari N, Ravi R, Gogtay NJ, Thatte UM. Recruitment and retention of the participants in clinical trials: challenges and solutions. Perspectives in Clinical Research. 2020.doi.orgRead: full text
  11. Cheng SK, Dietrich MS, Dilts DM. A sense of urgency: evaluating the link between clinical trial development time and the accrual performance of CTEP-sponsored studies. Clinical Cancer Research. 2010.pmc.ncbi.nlm.nih.govRead: full textAlso in review note 02
  12. Clinical Leader. Considerations for improving patient recruitment (white paper teaser).clinicalleader.comRead: full text (teaser page)
  13. Clinical Trials Arena (GlobalData). Clinical trial delays: America's patient recruitment dilemma. 2012.clinicaltrialsarena.comRead: full text
  14. Crocker JC, Ricci-Cabello I, Parker A, et al. Impact of patient and public involvement on enrolment and retention in clinical trials: systematic review and meta-analysis. BMJ. 2018.doi.orgRead: full textAlso in chapter 2Cited here
  15. DataAlly. Clinical trial enrollment statistics (secondary aggregator blog). 2025.dataally.aiRead: full text
  16. Desai M. Recruitment and retention of participants in clinical studies: critical issues and challenges (editorial). Perspectives in Clinical Research. 2020.doi.orgRead: full text
  17. Dombernowsky T, Haedersdal M, Lassen U, Thomsen SF. Criteria for site selection in industry-sponsored clinical trials: a survey among decision-makers in biopharmaceutical companies and clinical research organizations. Trials. 2019.doi.orgRead: abstract
  18. Donovan JL, Rooshenas L, Jepson M, et al. Optimising recruitment and informed consent in randomised controlled trials: the development and implementation of the Quintet Recruitment Intervention (QRI). Trials. 2016.doi.orgRead: full textAlso in chapter 2
  19. Fierce Biotech. New research from Tufts Center for the Study of Drug Development characterizes effectiveness of clinical trial enrollment (press release; page returned HTTP 403). 2013.fiercebiotech.comRead: index only
  20. Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemporary Clinical Trials Communications. 2018.doi.orgRead: full textAlso in chapter 2, chapter 3Cited here
  21. Gehring M, Taylor RS, Mellody M, et al. Factors influencing clinical trial site selection in Europe: the Survey of Attitudes towards Trial sites in Europe (the SAT-EU Study). BMJ Open. 2013.doi.orgRead: abstract
  22. Getz K. Enrollment performance: weighing the "facts". Applied Clinical Trials. 2012.appliedclinicaltrialsonline.comRead: full textAlso in chapter 3, chapter 8, review note 02, review note 03Cited here
  23. Getz K. How much does a day of delay in a clinical trial really cost? Applied Clinical Trials. 2024.appliedclinicaltrialsonline.comRead: full text
  24. Getz KA, Campo RA. New benchmarks characterizing growth in protocol design complexity. Therapeutic Innovation and Regulatory Science. 2018.doi.orgRead: abstractCited here
  25. Getz KA, Stergiopoulos S, Short M, et al. The impact of protocol amendments on clinical trial performance and cost. Therapeutic Innovation and Regulatory Science. 2016.doi.orgRead: abstractAlso in chapter 2, review note 03Cited here
  26. Getz KA, Wenger J, Campo RA, Seguine ES, Kaitin KI. Assessing the impact of protocol design changes on clinical trial performance. American Journal of Therapeutics. 2008.doi.orgRead: abstractAlso in chapter 2Cited here
  27. Gillies K, Kearney A, Keenan C, et al. Strategies to improve retention in randomised trials. Cochrane Database of Systematic Reviews. 2021.doi.orgRead: abstractAlso in chapter 4, review note 03Cited here
  28. Goyal A, Schibler T, Alhanti B, et al. Assessment of North American clinical research site performance during the start-up of large cardiovascular clinical trials. JAMA Network Open. 2021.doi.orgRead: abstract
  29. Healy P, Galvin S, Williamson PR, et al. Identifying trial recruitment uncertainties using a James Lind Alliance Priority Setting Partnership: the PRioRiTy study. Trials. 2018.doi.orgRead: full textAlso in review note 03Cited here
  30. HIT Consultant. If everyone claims to accelerate clinical trials, why are we still falling behind? (seen in search index only). 2026.hitconsultant.netRead: index only
  31. Houghton C, Dowling M, Meskell P, et al. Factors that impact on recruitment to randomised trials in health care: a qualitative evidence synthesis. Cochrane Database of Systematic Reviews. 2020.doi.orgRead: abstractCited here
  32. Huang GD, Bull J, Johnston McKee K, et al. Clinical trials recruitment planning: a proposed framework from the Clinical Trials Transformation Initiative. Contemporary Clinical Trials. 2018.doi.orgRead: abstractAlso in chapter 2Cited here
  33. Hulstaert L, Twick I, Sarsour K, Verstraete H. Enhancing site selection strategies in clinical trial recruitment using real-world data modeling. PLoS One. 2024.doi.orgRead: abstractAlso in chapter 3Cited here
  34. Institute of Medicine. A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program, summary chapter. 2010.nationalacademies.orgRead: full text
  35. IQVIA Institute. Global Trends in R&D 2025 (press release, 15 April 2025). 2025.iqvia.comRead: full text (press release)
  36. IQVIA Institute. Global R&D Trends 2026 (summary page, 25 March 2026). 2026.iqvia.comRead: abstract (summary page)
  37. Jacques RM, Ahmed R, Harper J, et al. Recruitment, consent and retention of participants in randomised controlled trials: a review of trials published in the NIHR Journals Library (1997-2020). BMJ Open. 2022.doi.orgRead: full textAlso in review note 03Cited here
  38. Johnson O. An evidence-based approach to conducting clinical trial feasibility assessments. Clinical Investigation. 2015.The original link no longer worksRead: index only (link dead; cited by reference 77 for the "80%" claim)
  39. Kasenda B, von Elm E, You J, et al. Prevalence, characteristics, and publication of discontinued randomized trials. JAMA. 2014.doi.orgRead: abstractAlso in chapter 2Cited here
  40. Kearney A, Harman NL, Rosala-Hallas A, et al. Development of an online resource for recruitment research in clinical trials to organise and map current literature. Clinical Trials. 2018.pmc.ncbi.nlm.nih.govRead: full text
  41. Knottnerus JA, Tugwell P. Prevention of premature trial discontinuation: how to counter Lasagna's law. Journal of Clinical Epidemiology. 2016.doi.orgRead: abstract
  42. Korn EL, Freidlin B, Mooney M, Abrams JS. Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007. Journal of Clinical Oncology. 2010.pmc.ncbi.nlm.nih.govRead: full textAlso in chapter 3
  43. Lab News. A fifth of cancer trial sites enrol only one patient. 2023.labnews.co.ukRead: full text
  44. Lasagna L. Problems in publication of clinical trial methodology. Clinical Pharmacology and Therapeutics. 1979.europepmc.orgRead: index onlyCited here
  45. Li G (Phesi). Phesi report: assessing single-patient investigator sites in cancer clinical trials. Applied Clinical Trials. 2023.appliedclinicaltrialsonline.comRead: full textAlso in chapter 3, chapter 8Cited here
  46. McDonald AM, Knight RC, Campbell MK, et al. What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials. 2006.doi.orgRead: full textAlso in chapter 2, chapter 3Cited here
  47. McDonald K, Saini KS, Lu M, et al. Quantifying the impact of the COVID-19 pandemic on clinical trial enrollment rates over time in 37 countries. Research Square preprint, 23 November 2022; version of record Trials 2023, DOI 10.1186/s13063-023-07277-1, record unreachable at time of writing. 2022.doi.orgRead: full text (preprint)Cited here
  48. Medidata Solutions. Non-enrolling and high-enrolling site data. Applied Clinical Trials. 2012.appliedclinicaltrialsonline.comRead: full text
  49. MESM (press release on Pharmaceutical Technology, GlobalData). Clinical research delays.pharmaceutical-technology.comRead: full text
  50. MRC Network of Hubs for Trials Methodology Research. SWAT and SWAR resources page.methodologyhubs.mrc.ac.ukRead: full text (web page)
  51. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004.doi.orgRead: abstract
  52. ORRCA. Online Resource for Research in Clinical triAls, viewed October 2026. 2026.orrca.org.ukRead: full text (web page)
  53. Phesi. News listing, viewed October 2026. 2026.phesi.comRead: index only (headlines)
  54. Regulatory Focus (RAPS). Study: clinical trial site activation, enrollment difficulties slow product approvals. 2013.raps.orgRead: full text
  55. Rooshenas L, Scott LJ, Blazeby JM, et al. The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation. Journal of Clinical Epidemiology. 2019.doi.orgRead: abstractAlso in chapter 2Cited here
  56. Sateren WB, Trimble EL, Abrams J, et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. Journal of Clinical Oncology. 2002.doi.orgRead: abstract
  57. Schroen AT, Petroni GR, Wang H, et al. Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clinical Trials. 2010.doi.orgRead: abstractAlso in chapter 3Cited here
  58. Schroen AT, Petroni GR, Wang H, et al. Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. Clinical Trials. 2011.doi.orgRead: abstractCited here
  59. Schroen AT, Petroni GR, Wang H, et al. Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from US Cooperative Oncology Groups. Clinical Cancer Research. 2012.doi.orgRead: abstract
  60. Smith B, Martin L, Martin S, et al. What drives site performance in clinical trials? Nature Reviews Drug Discovery. 2018.doi.orgRead: index only (paywalled)
  61. Smith Z, DiMasi J, Getz K. Quantifying the value of a day of delay in drug development (white paper). Tufts CSDD. 2024.csdd.tufts.eduRead: full textAlso in chapter 3Cited here
  62. Smith ZP, DiMasi JA, Getz KA. New estimates on the cost of a delay day in drug development. Therapeutic Innovation and Regulatory Science. 2024.doi.orgRead: abstractCited here
  63. Stensland KD, McBride RB, Latif A, et al. Adult cancer clinical trials that fail to complete: an epidemic? Journal of the National Cancer Institute. 2014.doi.orgRead: abstractAlso in chapter 2
  64. Sully BGO, Julious SA, Nicholl J. A reinvestigation of recruitment to randomised, controlled, multicenter trials: a review of trials funded by two UK funding agencies. Trials. 2013.doi.orgRead: full textAlso in chapter 2, chapter 3Cited here
  65. Tejeda HA, Green SB, Trimble EL, et al. Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. Journal of the National Cancer Institute. 1996.doi.orgRead: abstract
  66. Treweek S, Bevan S, Bower P, et al. Trial Forge Guidance 1: what is a Study Within A Trial (SWAT)? Trials. 2018.doi.orgRead: full text
  67. Treweek S, Pitkethly M, Cook J, et al. Strategies to improve recruitment to randomised trials. Cochrane Database of Systematic Reviews. 2018.doi.orgRead: full textAlso in chapter 2, chapter 3, chapter 4, review note 03Cited here
  68. Trial Forge. Home page and SWAT catalogue, viewed October 2026. 2026.trialforge.orgRead: full text (web page)
  69. Unger JM, Blanke CD, LeBlanc M, Hershman DL. Association of the coronavirus disease 2019 (COVID-19) outbreak with enrollment in cancer clinical trials. JAMA Network Open. 2020.doi.orgRead: full textAlso in chapter 7Cited here
  70. Unger JM, Cook E, Tai E, Bleyer A. The role of clinical trial participation in cancer research: barriers, evidence, and strategies. ASCO Educational Book. 2016.doi.orgRead: full text
  71. Unger JM, Hershman DL, Till C, et al. "When offered to participate": a systematic review and meta-analysis of patient agreement to participate in cancer clinical trials. Journal of the National Cancer Institute. 2021.doi.orgRead: full textAlso in chapter 4, review note 03Cited here
  72. Unger JM, Shulman LN, Facktor MA, et al. National estimates of the participation of patients with cancer in clinical research studies based on Commission on Cancer accreditation data. Journal of Clinical Oncology, as reported by The ASCO Post. 2024.ascopost.comRead: full text (news report)
  73. Unger JM, Vaidya R, Hershman DL, Minasian LM, Fleury ME. Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. Journal of the National Cancer Institute. 2019.doi.orgRead: full textAlso in chapter 2, chapter 3, chapter 4, review note 03Cited here
  74. van den Hoek TC, Ferrari MD. Reverse Lasagna's law: the ethics and undesirable consequences of overbooking patients for trials. European Journal of Neurology. 2023.doi.orgRead: abstract
  75. van der Wouden JC, Blankenstein AH, Huibers MJH, et al. Survey among 78 studies showed that Lasagna's law holds in Dutch primary care research. Journal of Clinical Epidemiology. 2007.doi.orgRead: abstractAlso in chapter 3Cited here
  76. Walters SJ, Bonacho dos Anjos Henriques-Cadby I, Bortolami O, et al. Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the UK Health Technology Assessment Programme. BMJ Open. 2017.doi.orgRead: full textAlso in chapter 2, chapter 3, review note 01, review note 02Cited here
  77. WCG. By the Numbers: six challenges to enrollment, one customized solution (cites Tufts CSDD Impact Report March/April 2017 and WCG proprietary data). About. 2017.wcgclinical.comRead: full text
  78. Whitham D, Turzanski J, Bradshaw L, et al. Development of a standardised set of metrics for monitoring site performance in multicentre randomised trials: a Delphi study. Trials. 2018.doi.orgRead: abstractAlso in review note 02

Chapter 2 Protocol and study design

  1. Angus DC, Berry S, Lewis RJ, et al. The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study: Rationale and Design. Ann Am Thorac Soc 17(7):879-891. 2020.doi.orgRead: abstract
  2. Applied Clinical Trials. Heavy burden: protocol design (May 2010; trade press, secondary). 2010.appliedclinicaltrialsonline.comRead: full text
  3. Beardsley E, Jefford M, Mileshkin L. Longer consent forms for clinical trials compromise patient understanding: so why are they lengthening? J Clin Oncol 25(9):e13-e14 (letter; figures not retrieved). 2007.doi.orgRead: index onlyCited here
  4. Bell SA, Tudur Smith C. A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov. Orphanet J Rare Dis 9:170. 2014.doi.orgRead: abstractCited here
  5. Botto E, Smith Z, Getz K. New Benchmarks on Protocol Amendment Experience in Oncology Clinical Trials. Ther Innov Regul Sci 58(4):645-654. 2024.doi.orgRead: abstractCited here
  6. Brown T, Jones T, Gove K, et al. Randomised controlled trials in severe asthma: selection by phenotype or stereotype. Eur Respir J 52(6):1801444. 2018.doi.orgRead: abstract
  7. Cameron D, Willoughby C, Messer D, Lux M, Aitken M, Getz K. Assessing Participation Burden in Clinical Trials: Introducing the Patient Friction Coefficient. Clin Ther 42(8):e150-e159. 2020.doi.orgRead: abstract
  8. Clinical Trials Transformation Initiative. Recruitment (recommendations landing page; key materials uploaded 2021). 2021.ctti-clinicaltrials.orgRead: index only
  9. Denicoff AM, Ivy SP, Tamashiro TT, et al. Implementing Modernized Eligibility Criteria in US National Cancer Institute Clinical Trials. J Natl Cancer Inst 114(11):1437-1440. 2022.doi.orgRead: abstract
  10. DiMasi JA, et al. Assessing the Financial Value of Decentralized Clinical Trials. Ther Innov Regul Sci 57(2):209-219. 2023.doi.orgRead: abstractCited here
  11. Dirks A, Botto E, Smith Z, Getz K. Trends in the Burden for Patients Participating in Industry-Funded Clinical Trials. Ther Innov Regul Sci 59(5):893-900. 2025.doi.orgRead: abstractCited here
  12. Donovan JL, Jepson M, Rooshenas L, et al. Development of a new adapted QuinteT Recruitment Intervention (QRI-Two). Trials 23:258. 2022.doi.orgRead: abstractCited here
  13. Dumville JC, Hahn S, Miles JNV, Torgerson DJ. The use of unequal randomisation ratios in clinical trials: a review. Contemp Clin Trials 27(1):1-12. 2006.doi.orgRead: abstractCited here
  14. European Medicines Agency. ICH E8(R1) General Considerations for Clinical Studies: EMA adoption page (first published 14 October 2021; effective 14 April 2022). 2021.ema.europa.euRead: index only
  15. Flaherty KT, Gray RJ, Chen AP, et al. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: NCI-MATCH. J Clin Oncol 38(33):3883-3894. 2020.doi.orgRead: abstractCited here
  16. Florez M, Smith Z, Olah Z, Martin M, Getz K. Quantifying Site Burden to Optimize Protocol Performance. Ther Innov Regul Sci 58(2):347-356. 2024.doi.orgRead: abstractCited here
  17. Getz K, Smith Z, Botto E, Murphy E, Dauchy A. New Benchmarks on Protocol Amendment Practices, Trends and their Impact on Clinical Trial Performance. Ther Innov Regul Sci 58(3):539-548. 2024.doi.orgRead: abstractCited here
  18. Getz K, Smith Z, Kravet M. Protocol Design and Performance Benchmarks by Phase and by Oncology and Rare Disease Subgroups. Ther Innov Regul Sci 57(1):49-56. 2023.pmc.ncbi.nlm.nih.govRead: full textCited here
  19. Getz KA. Improving Protocol Design Feasibility to Drive Drug Development Economics and Performance. Int J Environ Res Public Health 11(5):5069. 2014.pmc.ncbi.nlm.nih.govRead: full textCited here
  20. Harris MS, Wichary J, Zadnik M, Reinisch W. Competition for Clinical Trials in Inflammatory Bowel Diseases. Gastroenterology 157(6):1457-1461.e2 (editorial; paywalled, figures not retrieved). 2019.doi.orgRead: index only
  21. Harvey RD, Bruinooge SS, Chen L, et al. Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations. Clin Cancer Res 27(9):2430-2434 (conference version J Clin Oncol 37(suppl):LBA108, 2019). 2021.doi.orgRead: abstractCited here
  22. Harvey RD, et al. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group. Clin Cancer Res 27(9):2400-2407. 2021.doi.orgRead: abstractCited here
  23. Hoertel N and colleagues. Generalizability of pharmacologic and psychotherapy trial results for late-life unipolar depression. Aging Ment Health 25(2):367-377. 2021.doi.orgRead: abstract
  24. Hoertel N and colleagues (first author not captured in the record retrieved). Generalizability of Clinical Trial Results for Adolescent Major Depressive Disorder. Pediatrics 140(6):e20161701. 2017.doi.orgRead: abstract
  25. Hoertel N, et al. Generalizability of clinical trial results for generalized anxiety disorder to community samples. Depress Anxiety 29(7):614-620. 2012.doi.orgRead: abstract
  26. Hoertel N, et al. Generalizability of clinical trial results for bipolar disorder to community samples: findings from NESARC. J Clin Psychiatry 74(3):265-270. 2013.doi.orgRead: abstract
  27. Jenkins V, Fallowfield L. Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy. Br J Cancer 82(11):1783-1788. 2000.doi.orgRead: abstractAlso in chapter 4Cited here
  28. Jenkins V, Farewell V, Farewell D, et al. Drivers and barriers to patient participation in RCTs. Br J Cancer 108(7):1402-1407. 2013.doi.orgRead: abstractCited here
  29. Jones WS, Mulder H, Wruck LM, et al. Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease (ADAPTABLE). N Engl J Med. 2021.pmc.ncbi.nlm.nih.govRead: full textAlso in chapter 4
  30. Kim ES, Bruinooge SS, Roberts S, et al. Broadening Eligibility Criteria to Make Clinical Trials More Representative: ASCO and Friends of Cancer Research Joint Research Statement. J Clin Oncol 35(33):3737-3744. 2017.pmc.ncbi.nlm.nih.govRead: full textCited here
  31. Kim ES, Uldrick TS, Schenkel C, et al. Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement. Clin Cancer Res 27(9):2394-2399. 2021.doi.orgRead: abstractCited here
  32. Lee DH, et al. Treatment patterns across lines of therapy for advanced NSCLC by biomarker group (Flatiron Health). Cancer Med. 2026.doi.orgRead: abstractCited here
  33. Liu R, Rizzo S, Whipple S, et al. Evaluating eligibility criteria of oncology trials using real-world data and AI. Nature 592(7855):629-633. 2021.doi.orgRead: full textAlso in review note 03Cited here
  34. Masoudi FA, Havranek EP, Wolfe P, et al. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J 146(2):250-257. 2003.doi.orgRead: abstract
  35. Mills EJ, Seely D, Rachlis B, et al. Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncol 7(2):141-148. 2006.doi.orgRead: abstractAlso in chapter 4Cited here
  36. Nassif M, et al. Recruitment Strategies of a Decentralized Randomized Placebo Controlled Clinical Trial: The CHIEF-HF Trial. J Card Fail 29(6):863-869. 2023.doi.orgRead: abstractCited here
  37. Pablos-Méndez A, Barr RG, Shea S. Run-in periods in randomized trials: implications for the application of results in clinical practice. JAMA 279(3):222-225. 1998.doi.orgRead: abstractCited here
  38. Park JJH, Siden E, Zoratti MJ, et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials 20:572. 2019.doi.orgRead: abstract
  39. Park JW, Liu MC, Yee D, et al. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med 375(1):11-22. 2016.doi.orgRead: abstract
  40. PharmaTimes. Protocol complexity is increasing trial burden, Tufts study says (21 January 2008; trade press, secondary). 2008.pharmatimes.comRead: full text
  41. Pica N, Bourgeois F. Discontinuation and Nonpublication of Randomized Clinical Trials Conducted in Children. Pediatrics 138(3):e20160223. 2016.doi.orgRead: abstract
  42. Ran T, et al. Treatment patterns in EGFR-mutated metastatic NSCLC (Integra Connect real-world cohort). Cureus. 2025.doi.orgRead: abstractCited here
  43. RECOVERY Collaborative Group (Horby P, et al.). Dexamethasone in Hospitalized Patients with Covid-19 (preliminary report). N Engl J Med, published online 17 July. 2020.pmc.ncbi.nlm.nih.govRead: full text
  44. Schoenfeld AJ, et al. Non-driver mutation metastatic NSCLC: treatment patterns and attrition (COTA, 2015 to 2022). Future Oncol. 2025.doi.orgRead: abstractCited here
  45. Sevigny J, et al. Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial. Alzheimer Dis Assoc Disord (PMID 26885819). 2016.doi.orgRead: abstractCited here
  46. Sharp SM. Consent documents for oncology trials: does anybody read these things? Am J Clin Oncol 27(6):570-575. 2004.doi.orgRead: abstractCited here
  47. Sheffield KM, et al. KRAS G12C-mutant NSCLC after first-line therapy: real-world treatment patterns (US EHR and CGDB). Cancers 18(17):2869. 2026.doi.orgRead: abstractCited here
  48. Smith Z, Wilkinson M, Carney C, Grove N, Qutab B, Getz K. Enhancing the Measure of Participation Burden in Protocol Design to Incorporate Logistics, Lifestyle, and Demographic Characteristics. Ther Innov Regul Sci 55(6):1239-1249. 2021.doi.orgRead: abstractCited here
  49. Souza M, et al. Enrollment in Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials: A Pooled Analysis of Screen Failure Rates. Am J Gastroenterol. 2025.doi.orgRead: abstractCited here
  50. Sperling RA, Donohue MC, Raman R, et al. Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. JAMA Neurol 77(6):735-745. 2020.doi.orgRead: abstractCited here
  51. Spertus JA, et al. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nat Med 28(4):809-813. 2022.doi.orgRead: abstract
  52. Steg PG, López-Sendón J, Lopez de Sa E, et al. External validity of clinical trials in acute myocardial infarction. Arch Intern Med 167(1):68-73. 2007.doi.orgRead: abstract
  53. Taylor KM, Margolese RG, Soskolne CL. Physicians' reasons for not entering eligible patients in a randomized clinical trial of surgery for breast cancer. N Engl J Med 310(21):1363-1367. 1984.doi.orgRead: abstractCited here
  54. Travers J, et al. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax 62(3):219-223. 2007.doi.orgRead: abstract
  55. Travers J, et al. External validity of randomized controlled trials in COPD. Respir Med 101(6):1313-1320. 2007.doi.orgRead: abstract
  56. Tufts Center for the Study of Drug Development. Rising protocol complexity is hindering performance while driving up cost of clinical trials (press release, 17 July 2018; 9,737 protocols, 178 companies). 2018.biospace.comRead: full text
  57. Unger JM, Hershman DL, Fleury ME, Vaidya R. Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation. JAMA Oncol 5(3):326-333. 2019.doi.orgRead: abstractAlso in chapter 4Cited here
  58. US FDA. Cancer Clinical Trial Eligibility Criteria: Brain Metastases. Final guidance, July. 2020.fda.govRead: abstract
  59. US FDA. Cancer Clinical Trial Eligibility Criteria: Minimum Age Considerations for Inclusion of Pediatric Patients. Final guidance, July. 2020.fda.govRead: abstractCited here
  60. US FDA. Cancer Clinical Trial Eligibility Criteria: Patients with HIV, Hepatitis B Virus, or Hepatitis C Virus Infections. Final guidance, July. 2020.fda.govRead: abstract
  61. US FDA. Cancer Clinical Trial Eligibility Criteria: Patients with Organ Dysfunction or Prior or Concurrent Malignancies. Final guidance, July. 2020.fda.govRead: abstract
  62. US FDA. Conducting Clinical Trials With Decentralized Elements. Final guidance, September. 2024.fda.govRead: abstractAlso in chapter 7Cited here
  63. US FDA. Enhancing Participation in Clinical Trials: Eligibility Criteria, Enrollment Practices, and Trial Designs. Final guidance, December 2025 (earlier final version November 2020 titled Enhancing the Diversity of Clinical Trial Populations). 2025.fda.govRead: abstractAlso in chapter 5
  64. US FDA. Cancer Clinical Trial Eligibility Criteria: Performance Status. Final guidance, July. 2026.fda.govRead: abstract
  65. US FDA. Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications. Final guidance, July. 2026.fda.govRead: abstract
  66. US FDA. Cancer Clinical Trial Eligibility Criteria: Laboratory Values. Final guidance, July. 2026.fda.govRead: abstract
  67. Uzzan M, Bouhnik Y, Abreu M, et al. Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions. J Crohns Colitis 17(7):1066-1078. 2023.doi.orgRead: abstractCited here
  68. Vashisht P, Sayles H, Cannella AC, Mikuls TR, Michaud K. Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials. Arthritis Care Res 68(10):1478-1488. 2016.doi.orgRead: abstract
  69. Waksman R, et al. High screen failure rate in patients with resistant hypertension: Findings from SYMPLICITY HTN-3. Am Heart J. 2017.doi.orgRead: abstract
  70. Wang H, Yee D. I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer. Curr Breast Cancer Rep 11(4):303-310. 2019.doi.orgRead: abstract
  71. Welton AJ, Vickers MR, Cooper JA, Meade TW, Marteau TM. Is recruitment more difficult with a placebo arm in randomised controlled trials? A quasirandomised, interview based study. BMJ 318(7191):1114-1117. 1999.doi.orgRead: abstractCited here
  72. Wong SE, et al. Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies. Clin Genitourin Cancer. 2017.doi.orgRead: abstract
  73. Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry 159(3):469-473. 2002.doi.orgRead: abstract

Chapter 3 Sites, sponsors, and the machinery of start-up

  1. AACI Corporate Roundtable Trial Activation Task Force. Accelerating Clinical Trial Activation: a Collaborative Framework for Managing Pre-Activation Protocol Amendments. 2026.aaci-cancer.orgRead: full textCited here
  2. ACRP. Survey Identifies Factors in Reducing Clinical Research Coordinator Turnover (Buchanan and Claassen, Mayo Clinic Proceedings: Innovations, Quality and Outcomes). 2021.acrpnet.orgRead: full text
  3. ACRP. Fixing Feasibility: Collaborative Approaches for Redefining and Improving Site Selection. 2024.acrpnet.orgRead: full text
  4. ACRP. ACRP Publishes Results from First-Ever National Workforce Survey. 2025.acrpnet.orgRead: full text
  5. ACRP and TEConomy Partners. Special Report: An Assessment of the Adequacy of the Clinical Research Workforce (summary page).acrpnet.orgRead: abstract
  6. Advarra. The State of Clinical Trial Activation at Sites (Study Activation Report Survey). 2020.advarra.comRead: full textCited here
  7. Anisimov VV, Fedorov VV. Modelling, prediction and adaptive adjustment of recruitment in multicentre trials, Statistics in Medicine 26(27):4958-4975. 2007.doi.orgRead: abstractAlso in chapter 9
  8. Bechtel J (SCRS). The Results Are In: Survey Reveals Barriers and Opportunities In Site Sustainability, Clinical Leader. 2024.clinicalleader.comRead: full textCited here
  9. Bourne Partners. Incremental Insights into Clinical Trial Site Networks: Key Takeaways from the SCRS Global Site Solutions Summit (secondary report of the SCRS 2024 survey). 2024.media.bourne-partners.comRead: full textCited here
  10. Brosteanu O, et al. Risk-adapted monitoring is not inferior to extensive on-site monitoring: Results of the ADAMON cluster-randomised study, Clinical Trials 14(6):584-596. 2017.pmc.ncbi.nlm.nih.govRead: abstract
  11. Bruhn H, Treweek S, et al. Estimating Site Performance (ESP): can trial managers predict recruitment success at trial sites? An exploratory study, Trials 20:192. 2019.pmc.ncbi.nlm.nih.govRead: abstractAlso in review note 02Cited here
  12. Cheng SK, Dietrich MS, Dilts DM. Predicting accrual achievement: monitoring accrual milestones of NCI-CTEP-sponsored clinical trials, Clinical Cancer Research 17(7):1947-1955. 2011.pmc.ncbi.nlm.nih.govRead: abstractAlso in review note 02Cited here
  13. Clinical Research News. The Scope of Things: Source Preparation Emerges as a Clinical Trial Startup Bottleneck. 2026.clinicalresearchnewsonline.comRead: full text
  14. Clinical Trial Vanguard. Tufts CSDD: New Insights on the Clinical Trial Industry (Getz at SCOPE Summit). 2024.clinicaltrialvanguard.comRead: full textCited here
  15. Clinitiative Health Research. Research Brief RB-025: Coordinator Turnover and Workforce Stability Across the Site Network (vendor). 2026.clinitiative.comRead: full textCited here
  16. ClinOops (originally published by Power). When Competing Trials Start Eating Your Enrollment (vendor, anecdotal). 2026.clinoops.substack.comRead: full textCited here
  17. Contemporary Clinical Trials Communications. Trial-level factors affecting accrual and completion of oncology clinical trials: a systematic review. 2021.pmc.ncbi.nlm.nih.govRead: full text
  18. Cornea. Recruitment Strategies and Obstacles During the Zoster Eye Disease Study (PMID 39625123). 2024.pubmed.ncbi.nlm.nih.govRead: abstractCited here
  19. Corneli A, et al. One and done: Reasons principal investigators conduct only one FDA-regulated drug trial, Contemporary Clinical Trials Communications 6:31-38. 2017.pmc.ncbi.nlm.nih.govRead: full textCited here
  20. CRIO. What it takes to start a study: site start-up benchmarks (SASI analysis). 2026.clinicalresearch.ioRead: full textCited here
  21. Department of Health and Social Care and NIHR. UK Clinical Research Delivery key performance indicators: data to July 2026. 2026.gov.ukRead: full textCited here
  22. Dilts DM, Sandler AB. Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials, Journal of Clinical Oncology 24(28):4545-4552. 2006.pubmed.ncbi.nlm.nih.govRead: abstractCited here
  23. Dirks A, Chambers J, Getz K (Tufts CSDD). The Site Landscape Is Evolving, But How? Tufts CSDD Shares New Findings, Clinical Leader. 2026.clinicalleader.comRead: full textCited here
  24. Esin Attorney Partnership. Legal alert on Turkey's Regulation on Clinical Trials of Pharmaceuticals. 2023.esin.av.trRead: full textCited here
  25. Florence Healthcare. 2024 State of Technology Enabled Clinical Trials: Insights, Trends and Predictions. 2024.florencehc.comRead: full textCited here
  26. GC Trials. Turkey coverage page (vendor claims).gctrials.comRead: full text
  27. Gehring M, et al. Factors influencing clinical trial site selection in Europe: the SAT-EU Study, BMJ Open 3:e002957. 2013.pmc.ncbi.nlm.nih.govRead: abstract
  28. Getz K. Predicting Successful Site Performance, Applied Clinical Trials. 2011.appliedclinicaltrialsonline.comRead: full textCited here
  29. Getz K, Lamberti MJ, Chakravarthy R. New Benchmarks for Trial Initiation Activities, Applied Clinical Trials. 2016.appliedclinicaltrialsonline.comRead: full textAlso in review note 02Cited here
  30. Getz K, Smith Z, Peachey J, Li G. Leveraging Data Insights to Address the Perils of Linear Practices in Site Identification and Activation, Applied Clinical Trials. 2022.appliedclinicaltrialsonline.comRead: full textCited here
  31. Haidich AB, Ioannidis JP. Late-starter sites in randomized controlled trials, Journal of Clinical Epidemiology 56(5):408-415. 2003.pubmed.ncbi.nlm.nih.govRead: abstractCited here
  32. Hillery S, et al. Accelerating start-up cycles in investigator-initiated multicenter clinical trials, Journal of Clinical and Translational Science 9(1):e249. 2025.pmc.ncbi.nlm.nih.govRead: full text
  33. Hurtado-Chong A, Joeris A, Hess D, Blauth M. Improving site selection in clinical studies: a standardised, objective, multistep method and first experience results, BMJ Open 7:e014796. 2017.pmc.ncbi.nlm.nih.govRead: abstract
  34. Hutchinson N, Klas K, Carlisle BG, Polak M, Kimmelman J, Waligora M. Competition for recruitment in SARS-CoV-2 trials in the United States: a longitudinal cohort analysis, BMC Research Notes 15:368. 2022.pmc.ncbi.nlm.nih.govRead: full textCited here
  35. Ivsin P. The One-And-Done Investigator: A Clinical Trial Story, Clinical Leader. 2024.clinicalleader.comRead: full textCited here
  36. Labiotech. Cancer trials recruitment (report of the Phesi analysis). 2023.labiotech.euRead: full text
  37. Lamberti MJ, Dirks A, Howie R, Getz K. An Examination of the Role of the Clinical Research Associate and Factors Impacting Performance and Experience, Applied Clinical Trials. 2022.appliedclinicaltrialsonline.comRead: full textCited here
  38. Li G, Correa K, Peachey J, Legagneur V (Phesi). Enrollment Cycle Times Can and Should Be Optimized, Applied Clinical Trials. 2018.appliedclinicaltrialsonline.comRead: full textCited here
  39. Lord O'Shaughnessy. Commercial clinical trials in the UK: the Lord O'Shaughnessy review, final report. 2023.gov.ukRead: full textAlso in chapter 5, chapter 7Cited here
  40. Medical Research Agency (ABM), Poland. Model tripartite agreement of the Polish Clinical Trials Network now available. 2023.abm.gov.plRead: full text
  41. Ministry of Health and Family Welfare, India. New Drugs and Clinical Trials Rules, 2019 (G.S.R. 227(E)). 2019.cdsco.gov.inRead: full textCited here
  42. Miseta E. Getz: Site Activations Hurt By Commodity Mentality, Clinical Leader. 2016.clinicalleader.comRead: full textCited here
  43. Miseta E. Why Is Study Start-Up Still So Inefficient? (Tufts CSDD 2017 start-up study), Clinical Leader. 2017.clinicalleader.comRead: full textCited here
  44. Mitchell EJ, Godolphin PJ, Meakin G, Sprange K. Do investigator meetings improve recruitment rates in clinical trials? A retrospective before-and-after study of data from nine multi-centre clinical trials, Trials. 2020.pmc.ncbi.nlm.nih.govRead: full text
  45. Nelson S (WCG). Avoid Enrollment Pitfalls: Find Your Best-fit Clinical Trial Sites. 2018.wcgclinical.comRead: full textCited here
  46. Ninh A, Vu L, Butler D. Beyond prediction: an evidenced-based framework for assessing site selection decisions, Therapeutic Innovation and Regulatory Science. 2026.link.springer.comRead: full textCited here
  47. Parrish G, Minns LA. CRA Turnover Within Contract Research Organizations Post-COVID-19: A Cross-Sectional Study, Clinical Researcher 39(1). 2025.acrpnet.orgRead: full textCited here
  48. PharmaTimes. NIHR data reveals commercial study set up times reduce by a third. 2023.pharmatimes.comRead: full text
  49. PharmaVoice. Too much of a good thing? A flood of data is slowing clinical trials (Tufts CSDD data study). 2025.pharmavoice.comRead: full textCited here
  50. Preston NJ, et al. Strategies designed to help healthcare professionals to recruit participants to research studies, Cochrane Database of Systematic Reviews 2:MR000036. 2016.pmc.ncbi.nlm.nih.govRead: abstract
  51. Science 37. Science 37 and Tufts CSDD Publish Landmark Study on Direct-to-Patient Clinical Trial Site Performance (press release). 2026.science37.comRead: full text
  52. Scout Clinical. 2024 Site Landscape Survey and How Scout Lifts Lingering Site Burden (secondary report of the SCRS 2024 survey). 2025.explore.scoutclinical.comRead: full textCited here
  53. Shelford Group. Clinical trial setup performance and research activity across the Shelford Group (research dashboard; snippet only, not verified). 2026.dashboard.shelfordgroup.orgRead: index only
  54. Silverman E. What Patients? The Trouble With Trial Enrollment, Pharmalot (PDF copy). 2013.cctawareness.orgRead: full textCited here
  55. Smith S (WCG). Accelerating Clinical Trial Activation, Applied Clinical Trials. 2024.appliedclinicaltrialsonline.comRead: full textCited here
  56. Smith V, Clarke M, Begley C, Devane D. SWAT-1: the effectiveness of a 'site visit' intervention on recruitment rates in a multi-centre randomised trial, Trials. 2015.pmc.ncbi.nlm.nih.govRead: full text
  57. Smith Z, Getz K, Weinstein D, Jones L, McKee K, Van Horn T. Evaluating the Impact of a Direct-to-Patient Clinical Trial Site on Performance, Access, and Patient Representation, Applied Clinical Trials. 2026.appliedclinicaltrialsonline.comRead: full textCited here
  58. Snyder D, Freel S, Stroo M. Navigating Workforce Stability in Clinical Research, ACRP. 2025.acrpnet.orgRead: full text
  59. Society for Clinical Research Sites. Sites Speak Out on Clinical Trial Technology Overload: An SCRS Survey (377 respondents). 2020.myscrs.orgRead: full textCited here
  60. Society for Clinical Research Sites. Workforce Challenges at Clinical Research Sites. 2023.myscrs.orgRead: full textCited here
  61. Society for Clinical Research Sites. The 2023 Site Landscape Survey white paper. 2024.myscrs.orgRead: full textCited here
  62. Society for Clinical Research Sites. The Site Landscape: Benchmark Your Site, Part 1 (2025 SCRS European Site Landscape, European Site Solutions Summit slides). 2025.sitesolutionssummit.comRead: full text
  63. Society for Clinical Research Sites. White papers and guides listing page (links to the 2024 Site Landscape Survey White Paper and the 2025 SCRS Landscape Survey Report). 2025.myscrs.orgRead: index only
  64. Society for Clinical Research Sites. Payments Initiative.myscrs.orgRead: full text
  65. Society for Clinical Research Sites (survey distributed via Acurian). Meeting Clinical Trial Site Needs with Patient Recruitment Agency Services (315 responses). 2017.myscrs.orgRead: full text
  66. Society for Clinical Research Sites and Greenphire. Site Payments and Patient Reimbursements: A Global Perspective. 2017.myscrs.orgRead: full textCited here
  67. Stroo M, Reyes C, Deeter C, Freel SA, Gaudaur H, Sloane R, Snyder DC. Trends in turnover and turbulence at a large academic medical center before and during COVID-19, Journal of Clinical and Translational Science 9(1):e134. 2025.pmc.ncbi.nlm.nih.govRead: full textCited here
  68. Tang J, et al. Comprehensive analysis of the clinical immuno-oncology landscape, Annals of Oncology 29(1):84-91. 2018.pubmed.ncbi.nlm.nih.govRead: abstractCited here
  69. Trials. Assessing site performance in the Altair study, a multinational clinical trial (PMID 25872747). 2015.pmc.ncbi.nlm.nih.govRead: full textCited here
  70. Tufts Center for the Study of Drug Development. New Research from Tufts CSDD Characterizes Effectiveness and Variability of Patient Recruitment and Retention Practices (press release, BioSpace copy). 2013.biospace.comRead: full textCited here
  71. Tufts CSDD Impact Report 24(2). Cost variation and mis-estimation characterize clinical trial budgets. 2022.clinicaltrialvanguard.comRead: full textCited here
  72. van den Brink MJ, Hummel M, Lemstra M, Berger MY, Dekker JH, Blanker MH. Factors affecting patient recruitment to trials: qualitative research in general practice, BJGP Open 4(3). 2020.bjgpopen.orgRead: full text
  73. Wardyński and Partners. Legal framework for conducting clinical trials in Poland. 2023.m.wardynski.com.plRead: full textCited here
  74. WCG. 2024 Clinical Research Site Challenges Report. 2024.wcgclinical.comRead: full textCited here
  75. WCG. 2025 Site Challenges Report (611 sites). 2025.wcgclinical.comRead: full textCited here
  76. Whittaker R, Evans R, Santos S (PPD, Thermo Fisher Scientific). Optimizing Site Activation to Accelerate Clinical Trials, Clinical Leader white paper (vendor; body behind login).clinicalleader.comRead: index only
  77. Xtalks. Tufts Report and Removing the Blinders in Site Selection (webinar with K. Getz and goBalto). 2016.xtalks.comRead: full text
  78. Yang E, et al. Quantifying and visualizing site performance in clinical trials, Contemporary Clinical Trials Communications 9:108-114. 2018.pmc.ncbi.nlm.nih.govRead: full textCited here
  79. Yu M, Zhong S, Xing Y, Wang L (AbbVie). Enrollment Forecast for Clinical Trials at the Planning Phase with Study-Level Historical Data, arXiv:2303.08065. 2023.arxiv.orgRead: full text
  80. Zahren C, Harvey S, Weekes L, Bradshaw C, Butala R, Andrews J, O'Callaghan S. Clinical trials site recruitment optimisation: Guidance from Clinical Trials: Impact and Quality, Clinical Trials 18(5):594-605. 2021.pmc.ncbi.nlm.nih.govRead: full text

Chapter 4 Patients: barriers and what moves them

  1. 42 U.S.C. 289a-2, Inclusion of women and minorities in clinical research (NIH Revitalization Act of 1993 section 492B; amended by Pub. L. 114-255, 2016). 1993.law.cornell.eduRead: full text
  2. 42 U.S.C. 300gg-8, Coverage for individuals participating in approved clinical trials (ACA section 2709; added by Pub. L. 111-148 section 10103(c)). 2010.law.cornell.eduRead: full text
  3. 42 U.S.C. 1396d(gg), Routine patient costs for items and services furnished in connection with participation in qualifying clinical trials (Clinical Treatment Act; added by Pub. L. 116-260 section 210(a)(2)). 2020.law.cornell.eduRead: full textCited here
  4. AgencyIQ. FDA begins restoring some documents following court order. 2025.agencyiq.comRead: full textAlso in chapter 5Cited here
  5. Albrecht TL, Eggly SS, Gleason ME, et al. Influence of clinical communication on patients' decision making on participation in clinical trials. J Clin Oncol 26(16):2666–2673. 2008.pubmed.ncbi.nlm.nih.govRead: abstract
  6. Alsan M, Wanamaker M. Tuskegee and the health of black men. Q J Econ 133(1):407–455. 2018.pmc.ncbi.nlm.nih.govRead: full textCited here
  7. Antidote. Vendor site, accessed 21 October 2026. 2026.antidote.meRead: index only
  8. Apostolaros M, Babaian D, Corneli A, et al. Legal, regulatory, and practical issues to consider when adopting decentralized clinical trials: recommendations from the Clinical Trials Transformation Initiative. Ther Innov Regul Sci 54(4):779–787. 2020.pmc.ncbi.nlm.nih.govRead: full text
  9. Applied Clinical Trials. Education and satisfaction disparities evident among European patients, public (CISCRP 2013 wave, n = 5,701). 2013.appliedclinicaltrialsonline.comRead: full text
  10. Applied Clinical Trials. Medicaid coverage of "routine costs" for clinical trials.appliedclinicaltrialsonline.comRead: full text
  11. ASCO Post. Implementation of CLINICAL TREATMENT Act advances, increasing access to cancer clinical trials. 2023.ascopost.comRead: full text
  12. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine (COVE). N Engl J Med 384:403–416. 2021.pmc.ncbi.nlm.nih.govRead: full textCited here
  13. Bell S, Clarke R, Mounier-Jack S, Walker JL, Paterson P. Parents' and guardians' views on the acceptability of a future COVID-19 vaccine: a multi-methods study in England. Vaccine. 2020.pubmed.ncbi.nlm.nih.govRead: abstract
  14. Borno HT, Zhang L, Siegel A, Chang E, Ryan CJ. At what cost to clinical trial enrollment? A retrospective study of patient travel burden in cancer clinical trials. Oncologist 23(10):1242–1249. 2018.pmc.ncbi.nlm.nih.govRead: full text
  15. Bryant J, Powell J. Payment to healthcare professionals for patient recruitment to trials: a systematic review. BMJ 331(7529):1377–1378. 2005.doi.orgRead: full textAlso in review note 03
  16. Byrne LM, Cook SK, Kennedy N, et al. Opening doors to clinical trial participation among Hispanics: lessons learned from the Spanish translation of ResearchMatch. J Clin Transl Sci. 2020.pmc.ncbi.nlm.nih.govRead: full text
  17. Caldwell PH, Hamilton S, Tan A, Craig JC. Strategies for increasing recruitment to randomised controlled trials: systematic review. PLoS Med 7(11):e1000368. 2010.pmc.ncbi.nlm.nih.govRead: full text
  18. Cartmell KB, Bonilha HS, Simpson KN, Ford ME, Bryant DC, Alberg AJ. Patient barriers to cancer clinical trial participation and navigator activities to assist. Adv Cancer Res 146:139–166. 2020.pmc.ncbi.nlm.nih.govRead: full text
  19. Centers for Medicare and Medicaid Services. National Coverage Determination 310.1, Routine Costs in Clinical Trials (version 2, effective 9 July 2007; superseded 27 May 2024). 2007.cms.govRead: full text
  20. Chansky MC, et al. Process and outcome evaluation of the NIH Community Engagement Alliance. Public Health Rep. 2026.pubmed.ncbi.nlm.nih.govRead: abstract
  21. Cheng AC, et al. ResearchMatch on FHIR: development and evaluation of a recruitment registry and EHR system interface for volunteer profile completion. J Clin Transl Sci. 2023.pmc.ncbi.nlm.nih.govRead: full text
  22. CISCRP. 2019 Perceptions and Insights Study: Deciding to Participate (report deck, n = 12,451). 2019.ciscrp.orgRead: full text
  23. CISCRP. 2023 Perceptions and Insights Study: Deciding to Participate (report deck, n = 12,017). 2024.ciscrp.orgRead: full text
  24. CISCRP. Results from CISCRP's 2023 Perceptions and Insights Study (web summary). 2024.legacy.ciscrp.orgRead: full text
  25. Clinical Trials Arena. Judge orders FDA to reinstate clinical trial diversity webpages. 2025.clinicaltrialsarena.comRead: full textCited here
  26. Clinical Trials Transformation Initiative. CTTI Recommendations: Decentralized Clinical Trials. 2018.ctti-clinicaltrials.orgRead: full text
  27. CNBC. Moderna slows coronavirus vaccine trial enrollment to ensure minority representation, CEO says (figures as reported; page not directly retrievable). 2020.cnbc.comRead: index only
  28. Comis RL, Miller JD, Aldigé CR, Krebs L, Stoval E. Public attitudes toward participation in cancer clinical trials. J Clin Oncol 21(5):830–835. 2003.pubmed.ncbi.nlm.nih.govRead: abstract
  29. Coyle J, et al. Learning from remote decentralised clinical trial experiences: a qualitative analysis of interviews with trial personnel, patient representatives and other stakeholders. Br J Clin Pharmacol. 2022.pubmed.ncbi.nlm.nih.govRead: abstractCited here
  30. Daniel N, et al. Enablers and barriers to participation in vaccine trials: a narrative synthesis. Vaccine. 2026.pubmed.ncbi.nlm.nih.govRead: abstract
  31. Davis S, et al. Ethics committees and the changed clinical research environment in India in 2016: a perspective. Perspect Clin Res. 2017.pubmed.ncbi.nlm.nih.govRead: abstract
  32. Day S, et al. Barriers and facilitators of participation in syphilis vaccine trials: a qualitative analysis to inform trial design and community engagement in the United States. Sex Reprod Health Matters. 2024.pubmed.ncbi.nlm.nih.govRead: abstract
  33. Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico (PREVENT-19). N Engl J Med 386(6):531–543. 2022.pmc.ncbi.nlm.nih.govRead: full text
  34. Edwards PJ, Roberts I, Clarke MJ, et al. Methods to increase response to postal and electronic questionnaires. Cochrane Database Syst Rev 3:MR000008. 2009.pubmed.ncbi.nlm.nih.govRead: abstract
  35. Embi PJ, Jain A, Clark J, Bizjack S, Hornung R, Harris CM. Effect of a clinical trial alert system on physician participation in trial recruitment. Arch Intern Med 165(19):2272–2277. 2005.pmc.ncbi.nlm.nih.govRead: full textCited here
  36. Embi PJ, Leonard AC. Evaluating alert fatigue over time to EHR-based clinical trial alerts: findings from a randomized controlled study. J Am Med Inform Assoc. 2012.pubmed.ncbi.nlm.nih.govRead: abstract
  37. Enama ME, Hu Z, Gordon I, Costner P, Ledgerwood JE, Grady C. Randomization to standard and concise informed consent forms: development of evidence-based consent practices. Contemp Clin Trials 33(5):895–902. 2012.pmc.ncbi.nlm.nih.govRead: full text
  38. Fioravanti P, et al. Analysis of registered clinical trials in Italy regarding dermatology (2003–2022). Ital J Dermatol Venereol. 2024.pubmed.ncbi.nlm.nih.govRead: abstract
  39. Fletcher I, et al. A qualitative study to explore how to increase participation of South Asian women in gestational diabetes clinical trials. Research Square preprint. 2026.europepmc.orgRead: abstract
  40. Ford JG, Howerton MW, Lai GY, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer 112(2):228–242. 2008.pubmed.ncbi.nlm.nih.govRead: abstract
  41. Fouad MN, Acemgil A, Bae S, et al. Patient navigation as a model to increase participation of African Americans in cancer clinical trials. J Oncol Pract 12(6):556–563. 2016.pmc.ncbi.nlm.nih.govRead: full textCited here
  42. Frampton GK, Shepherd J, Pickett K, Griffiths G, Wyatt JC. Digital tools for the recruitment and retention of participants in randomised controlled trials: a systematic map. Trials 21:478. 2020.pmc.ncbi.nlm.nih.govRead: full text
  43. Galsky MD, Stensland KD, McBride RB, et al. Geographic accessibility to clinical trials for advanced cancer in the United States. JAMA Intern Med 175(2):293–295. 2015.doi.orgRead: index only
  44. Goel K, et al. Community health workers' willingness to participate in COVID-19 vaccine trials and intention to vaccinate: a cross-sectional survey in India. Clin Epidemiol Glob Health. 2022.pubmed.ncbi.nlm.nih.govRead: abstract
  45. Goodson N, et al. Opportunities and counterintuitive challenges for decentralized clinical trials to broaden participant inclusion. NPJ Digit Med. 2022.pubmed.ncbi.nlm.nih.govRead: abstractCited here
  46. Gota V, et al. Quality of informed consent in cancer clinical trials in India: a cross-sectional survey. Natl Med J India. 2018.pubmed.ncbi.nlm.nih.govRead: abstract
  47. Halpern SD, Chowdhury M, Bayes B, et al. Effectiveness and ethics of incentives for research participation: 2 randomized clinical trials. JAMA Intern Med 181(11):1479–1488. 2021.doi.orgRead: full textAlso in review note 03
  48. Hamel LM, Penner LA, Albrecht TL, Heath E, Gwede CK, Eggly S. Barriers to clinical trial enrollment in racial and ethnic minority patients with cancer. Cancer Control 23(4):327–337. 2016.pmc.ncbi.nlm.nih.govRead: abstractCited here
  49. Harris PA, Scott KW, Lebo L, Hassan N, Lightner C, Pulley J. ResearchMatch: a national registry to recruit volunteers for clinical research. Acad Med. 2012.pmc.ncbi.nlm.nih.govRead: full text
  50. Health Research Authority (NREAP). HRA Ethics Guidance: Payments and Incentives in Research, v1.0. 2014.s3.eu-west-2.amazonaws.comRead: full text
  51. Healthcare Innovation. New law requires Medicaid coverage of clinical trial participation. 2021.hcinnovationgroup.comRead: full text
  52. Heller C, Balls-Berry JE, Nery JD, et al. Strategies addressing barriers to clinical trial enrollment of underrepresented populations: a systematic review. Contemp Clin Trials 39(2):169–182. 2014.pubmed.ncbi.nlm.nih.govRead: abstract
  53. Hewston P, et al. Virtual GERAS DANcing for Cognition Exercise (DANCE) for older adults at home: a randomized feasibility trial. Pilot Feasibility Stud. 2026.pubmed.ncbi.nlm.nih.govRead: abstractCited here
  54. Hilal O, et al. Connecting patients with clinical trials using patient navigation: a scoping review. Curr Oncol. 2026.pubmed.ncbi.nlm.nih.govRead: abstract
  55. Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341(27):2061–. 1999.pubmed.ncbi.nlm.nih.govRead: abstractCited here
  56. Jin X, Chandramouli C, Allocco B, Gong E, Lam CSP, Yan LL. Women's participation in cardiovascular clinical trials from 2010 to 2017. Circulation 141(7):540–548. 2020.pubmed.ncbi.nlm.nih.govRead: abstract
  57. Journal for Clinical Studies. Clinical trial in Central and Eastern Europe (industry). 2017.journalforclinicalstudies.comRead: full text
  58. Khubchandani J, et al. COVID-19 vaccination hesitancy in the United States: a rapid national assessment. J Community Health. 2021.pubmed.ncbi.nlm.nih.govRead: abstract
  59. Kimmick GG, Peterson BL, Kornblith AB, et al. Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001. J Clin Oncol 23(10):2201–2207. 2005.pubmed.ncbi.nlm.nih.govRead: abstractCited here
  60. King TL, et al. Malaysian patient perspectives on clinical trial participation: willingness, knowledge, perceptions, confidence, and religious barriers. Research Square preprint (later Sci Rep 2025). 2023.europepmc.orgRead: abstract
  61. Knapp P, Bower P, Lidster A, et al. Why do patients take part in research? An updated overview of systematic reviews of psychosocial barriers and facilitators. Trials 26:174 (original: Sheridan R, et al. Trials 21:259, 2020). 2025.pmc.ncbi.nlm.nih.govRead: full text
  62. Kripalani S, et al. Disparities in research participation by level of health literacy. Mayo Clin Proc. 2021.pubmed.ncbi.nlm.nih.govRead: abstract
  63. Kubilay Tolunay P, Erol C, Kahraman S, et al. Understanding of clinical trials among patients with cancer and their relatives. JAMA Netw Open 8(1):e2457020. 2025.jamanetwork.comRead: full text
  64. Lawrie K, et al. An exploration of the intersection of clinical trials and health literacy: a scoping review. J Health Care Poor Underserved. 2026.pubmed.ncbi.nlm.nih.govRead: abstract
  65. Loree JM, Anand S, Dasari A, et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol 5(10):e191870 (read through the ASCO Post summary). 2019.ascopost.comRead: abstractCited here
  66. Ludmir EB, Mainwaring W, Lin TA, et al. Factors associated with age disparities among cancer clinical trial participants. JAMA Oncol 5(12):1769–1773. 2019.pmc.ncbi.nlm.nih.govRead: full textCited here
  67. Ma JE, et al. Provider interaction with an electronic health record notification to identify eligible patients for a cluster randomized trial of advance care planning in primary care: secondary analysis. J Med Internet Res. 2023.pubmed.ncbi.nlm.nih.govRead: abstract
  68. Makhnoon S, et al. Implementation of a patient navigation program to support representative participation in cancer clinical trials. Cancer Med. 2025.pubmed.ncbi.nlm.nih.govRead: abstract
  69. Marmara Medical Journal. Patients' motivation about clinical trials: a local perspective from Turkey (survey of 504 patients, Istanbul, 2008). 2011.openaccess.marmara.edu.trRead: abstract
  70. Marquis-Gravel G, et al. Rationale and design of the Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) trial. JAMA Cardiol 5(5):598–607. 2020.pubmed.ncbi.nlm.nih.govRead: abstract
  71. Mendiratta J, et al. Representation from India in multinational, interventional, phase 2 or 3 trials registered in Clinical Trials Registry-India: a cross-sectional study. PLoS One. 2023.pubmed.ncbi.nlm.nih.govRead: abstract
  72. Mensah GA, et al. Community Engagement Alliance (CEAL): a National Institutes of Health program to advance health equity. Am J Public Health 114(S1):S12–S17. 2024.pmc.ncbi.nlm.nih.govRead: full text
  73. Moseson H, et al. Comparison of study samples recruited with virtual versus traditional recruitment methods. Contemp Clin Trials Commun. 2020.pubmed.ncbi.nlm.nih.govRead: abstractCited here
  74. Muthukumar AV, Morrell W, Bierer BE. Evaluating the frequency of English language requirements in clinical trial eligibility criteria: a systematic analysis using ClinicalTrials.gov. PLoS Med 18(9):e1003758. 2021.pmc.ncbi.nlm.nih.govRead: full textCited here
  75. Nair A. Clinical research: regulatory uncertainty hits drug trials in India. Pharmaceutical Journal. 2015.pharmaceutical-journal.comRead: full textCited here
  76. NBC News (Reuters). Moderna vaccine trial contractors fail to enroll enough people of color, prompting slowdown. 2020.nbcnews.comRead: full textCited here
  77. NIHR Be Part of Research. Over half a million people sign up to Be Part of Research. 2024.bepartofresearch.nihr.ac.ukRead: full text
  78. Nipp RD, Lee H, Powell E, et al. Financial burden of cancer clinical trial participation and the impact of a Cancer Care Equity Program. Oncologist 21(4):467–474. 2016.doi.orgRead: full text
  79. Nishimura A, Carey J, Erwin PJ, Tilburt JC, Murad MH, McCormick JB. Improving understanding in the research informed consent process: a systematic review of 54 interventions tested in randomized control trials. BMC Med Ethics 14:28. 2013.pmc.ncbi.nlm.nih.govRead: full text
  80. Nkoy FL, et al. Enhancing an existing clinical information system to improve study recruitment and census gathering efficiency. AMIA Annu Symp Proc. 2009.pubmed.ncbi.nlm.nih.govRead: abstract
  81. Perez MV, Mahaffey KW, Hedlin H, et al. Large-scale assessment of a smartwatch to identify atrial fibrillation (Apple Heart Study). N Engl J Med 381(20):1909–. 2019.pubmed.ncbi.nlm.nih.govRead: abstract
  82. Pew Research Center. Internet/Broadband Fact Sheet (NPORS 2026). 2026.pewresearch.orgRead: full textCited here
  83. PharmaTimes. Poland's cup runs over with clinical trials (industry commentary).pharmatimes.comRead: full text
  84. Pillai GS, et al. Knowledge and perception of health-care professionals on clinical trials in India: a pan-Indian cross-sectional survey. Indian J Ophthalmol. 2023.pubmed.ncbi.nlm.nih.govRead: abstract
  85. Pillai GS, et al. Knowledge and awareness of clinical trials among trial participants in India: a multicentric questionnaire-based cross-sectional study. Indian J Ophthalmol. 2024.pubmed.ncbi.nlm.nih.govRead: abstract
  86. Porter G. Regulating clinical trials in India: the economics of ethics. Dev World Bioeth. 2018.pubmed.ncbi.nlm.nih.govRead: abstract
  87. Raftery J, Bryant J, Powell J, Kerr C, Hawker S. Payment to healthcare professionals for patient recruitment to trials: systematic review and qualitative study. Health Technol Assess 12(10). 2008.pubmed.ncbi.nlm.nih.govRead: abstract
  88. Ranjan R, et al. Factors influencing participation of healthy volunteers in clinical trials: findings from a cross-sectional study in Delhi, North India. Patient Prefer Adherence. 2019.pubmed.ncbi.nlm.nih.govRead: abstract
  89. Redacción Médica. España da un salto cualitativo en investigación clínica en una década (Farmaindustria). 2017.redaccionmedica.comRead: full text
  90. Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use, Articles 28 and 31 (text on legislation.gov.uk). 2014.legislation.gov.ukRead: full text
  91. ResearchMatch. Site counters, accessed 21 October 2026. 2026.researchmatch.orgRead: index only
  92. Roy Chaudhury R. Regulatory developments in the conduct of clinical trials in India. Glob Health Epidemiol Genom. 2016.pubmed.ncbi.nlm.nih.govRead: abstractAlso in chapter 6Cited here
  93. Sariola S, et al. How civil society organisations changed the regulation of clinical trials in India. Sci Cult. 2019.pubmed.ncbi.nlm.nih.govRead: abstract
  94. Scharff DP, Mathews KJ, Jackson P, Hoffsuemmer J, Martin E, Edwards D. More than Tuskegee: understanding mistrust about research participation. J Health Care Poor Underserved 21(3):879–897. 2010.pmc.ncbi.nlm.nih.govRead: full text
  95. Sedrak MS, Freedman RA, Cohen HJ, et al. Older adult participation in cancer clinical trials: a systematic review of barriers and interventions. CA Cancer J Clin 71(1):78–92. 2021.pmc.ncbi.nlm.nih.govRead: full textCited here
  96. Sommer C, Zuccolin D, Arnera V, et al. Building clinical trials around patients: evaluation and comparison of decentralized and conventional site models in patients with low back pain. Contemp Clin Trials Commun 11:120–126. 2018.pmc.ncbi.nlm.nih.govRead: full text
  97. Steinberg JR, Turner BE, Weeks BT, et al. Analysis of female enrollment and participant sex by burden of disease in US clinical trials between 2000 and 2020. JAMA Netw Open 4(6):e2113749. 2021.pmc.ncbi.nlm.nih.govRead: full text
  98. Synnot A, Ryan R, Prictor M, Fetherstonhaugh D, Parker B. Audio-visual presentation of information for informed consent for participation in clinical trials. Cochrane Database Syst Rev 5:CD003717. 2014.pmc.ncbi.nlm.nih.govRead: full text
  99. Terraneo M, et al. Social capital and willingness to participate in COVID-19 vaccine trials: an Italian case-control study. BMC Public Health. 2022.pubmed.ncbi.nlm.nih.govRead: abstract
  100. The Pharma Letter. Spain above the European average in clinical trials in oncology (Farmaindustria data).thepharmaletter.comRead: full text
  101. Turner BE, Steinberg JR, Weeks BT, Rodriguez F, Cullen MR. Race/ethnicity reporting and representation in US clinical trials: a cohort study. Lancet Reg Health Am 11:100252. 2022.pmc.ncbi.nlm.nih.govRead: full textCited here
  102. Turner L, et al. Faith, culture, and cancer: a qualitative study exploring Muslim women's perspectives on clinical trials in the United Kingdom. Health Expect. 2026.pubmed.ncbi.nlm.nih.govRead: abstract
  103. Unger JM, Coltman CA, Crowley JJ, et al. Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. J Clin Oncol 24(1):141–144. 2006.pubmed.ncbi.nlm.nih.govRead: abstractCited here
  104. Unger JM, Hershman DL, Albain KS, et al. Patient income level and cancer clinical trial participation. J Clin Oncol 31(5):536–542. 2013.pmc.ncbi.nlm.nih.govRead: full text
  105. Unger JM, Moseley A, Symington B, Chavez-MacGregor M, Ramsey SD, Hershman DL. Geographic distribution and survival outcomes for rural patients with cancer treated in clinical trials. JAMA Netw Open 1(4):e181235. 2018.pmc.ncbi.nlm.nih.govRead: full text
  106. Unger JM, Xiao H, Vaidya R, Hershman DL. Medicaid expansion of the Patient Protection and Affordable Care Act and participation of patients with Medicaid in cancer clinical trials. JAMA Oncol 9(10):1371–1379. 2023.pmc.ncbi.nlm.nih.govRead: full text
  107. US Food and Drug Administration. Payment and Reimbursement to Research Subjects: Information Sheet. 2018.fda.govRead: full text
  108. US Food and Drug Administration. Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies: draft guidance page (court-order notice). 2024.fda.govRead: index onlyAlso in chapter 5
  109. US Food and Drug Administration, CDER. Drug Trials Snapshots Summary Report 2024. 2025.fda.govRead: full textCited here
  110. Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 297(11):1233–1240. 2007.pubmed.ncbi.nlm.nih.govRead: abstractCited here
  111. Vozpópuli. España consolida su liderazgo en ensayos clínicos pese a las trabas a la investigación (reporting IQVIA for EFPIA). 2024.vozpopuli.comRead: full text
  112. Whitaker C, Stevelink S, Fear N. The use of Facebook in recruiting participants for health research purposes: a systematic review. J Med Internet Res 19(8):e290. 2017.pmc.ncbi.nlm.nih.govRead: full textCited here
  113. Youssef E, et al. Understanding the barriers and enablers to participation in vaccine trials in a pregnant population from diverse ethnic background in an inner-city UK hospital. PLoS One. 2024.pubmed.ncbi.nlm.nih.govRead: abstract
  114. Zhang D, et al. Compromised informed consent due to functional health literacy challenges in Chinese hospitals. BMC Med Ethics. 2024.pubmed.ncbi.nlm.nih.govRead: abstract

Chapter 5 Countries and policy: the United States, the United Kingdom, and the European Union

  1. ABPI. Rescuing patient access to industry clinical trials in the UK. 2022.abpi.org.ukRead: full textAlso in chapter 8Cited here
  2. ABPI. Written evidence to the House of Commons Health and Social Care Committee. 2022/23. 2022.committees.parliament.ukRead: full text
  3. ABPI. Restoring the UK's global position in industry clinical trials (position paper). 16 November. 2023.abpi.org.ukRead: full text
  4. ABPI. The road to recovery for UK industry clinical trials. December. 2024.abpi.org.ukRead: full textCited here
  5. ABPI. UK industry clinical trials: translating actions into impact. 2 December. 2025.abpi.org.ukRead: full text
  6. ABPI. Decline in commercial clinical trial recruitment selling patients short, says ABPI. 2 December. 2025.abpi.org.ukRead: full text
  7. ACSM Policy Corner. Federal government shutdown ends. November. 2025.acsm.orgRead: full text
  8. ACSM Policy Corner. Court prevents NIH research award indirect cost cap policy, and another shutdown deadline approaches. 20 January. 2026.acsm.orgRead: full text
  9. ACSM Policy Corner. February 2026 update. February. 2026.acsm.orgRead: full text
  10. ACT EU. Accelerating clinical trials in the EU (homepage KPIs, data to end of June 2026). 2026.accelerating-clinical-trials.europa.euRead: full textCited here
  11. ACT EU and EMA. EU clinical trials during the 3-year CTR transition period (31 January 2022 to 30 January 2025). 2025.accelerating-clinical-trials.europa.euRead: full textCited here
  12. AIFA. Ethics Committees Coordination Centre (Centro di Coordinamento Nazionale dei Comitati Etici). 2025.aifa.gov.itRead: full textCited here
  13. AIFA. Clinical trials concerning medicinal products. 2025.aifa.gov.itRead: full text
  14. American Council on Education. Trump administration does not seek to appeal to Supreme Court; indirect costs cap litigation concluded. 2026.acenet.eduRead: full text
  15. Bennett Institute, University of Oxford. UK trials and Brexit. May. 2019.bennett.ox.ac.ukRead: full text
  16. BfArM. Clinical trials (page). 2025.bfarm.deRead: index only
  17. BioPharma Dive. HHS to cut 10,000 staff in major restructuring under RFK Jr. 27 March. 2025.biopharmadive.comRead: full text
  18. British Journal of Cancer. Oncology drug development in the UK: analysis of the past 25 years and focus on the 2026 reboot of the clinical trial regulatory framework. 23 July. 2026.nature.comRead: full textCited here
  19. CCMO (Netherlands). English site (no statistics retrieved). 2025.english.ccmo.nlRead: index only
  20. CDC. ACIP membership roster. 2025.cdc.govRead: full text
  21. Cięszczyk et al. (PMC11270168). Knowledge and beliefs about clinical trials among adults in Poland. Clinics and Practice. 2024.pmc.ncbi.nlm.nih.govRead: full text
  22. Clinical Trials Arena. FDA winds down operations amid government shutdown. 2 October. 2025.clinicaltrialsarena.comRead: full text
  23. Clinical Trials Arena. Reforms to UK clinical trial sector showing signs of success. 2026.clinicaltrialsarena.comRead: full text
  24. Clinical Trials Arena. EU region sees increase in multinational trial initiation in Q1 2026. 21 May. 2026.clinicaltrialsarena.comRead: full text
  25. CMS. NCD 310.1 Routine costs in clinical trials. 2007.cms.govRead: full text
  26. Danish Medicines Agency. Clinical trials with medicinal products (updated 21 October 2026). 2026.laegemiddelstyrelsen.dkRead: full textCited here
  27. Department of Health and Social Care. Full government response to the Lord O'Shaughnessy review into commercial clinical trials. 26 May 2023, updated 8 December. 2023.gov.ukRead: full text
  28. EFPIA. 35,000 more patients to get access to clinical trials if new EU targets are met. 24 February. 2026.efpia.euRead: full text
  29. EMA. Clinical trials: transition to new EU system, one year left. 31 January. 2024.ema.europa.euRead: full text
  30. EMA. Health technology assessment bodies. 2025.ema.europa.euRead: full text
  31. EMA. Clinical Trials Information System (CTIS) (page updated 2026, CTIS task force). 2026.ema.europa.euRead: full text
  32. European Commission. Reform of the EU pharmaceutical legislation (political agreement December 2025). 2025.health.ec.europa.euRead: full text
  33. European Commission. Health technology assessment: overview (Regulation (EU) 2021/2282). 2025.health.ec.europa.euRead: full text
  34. Farmaindustria. The Great Opportunity: Spain as a Global Hub for Pharmaceutical Innovation and Manufacturing. November. 2025.farmaindustria.esRead: full text
  35. FDA. 21st Century Cures Act. 2025.fda.govRead: full text
  36. Fierce Biotech. U.K. government-backed medical research shut down amid COVID-19. March. 2020.fiercebiotech.comRead: full text
  37. Fierce Biotech. NIH research grinds to a halt as government shuts down; and ASCO. Federal government shuts down after Congress fails to pass FY26 funding bill. October. 2025.fiercebiotech.comRead: index only
  38. Fierce Pharma. FDA staff cuts could disrupt drug reviews, putting agency's critical funding programs at risk. 2025.fiercepharma.comRead: index only
  39. Forbes. Appeals court upholds ban against fed's plan to cap NIH indirect costs. 6 January. 2026.forbes.comRead: full text
  40. GOV.UK. Government drives forward its 150-day clinical trial target. 15 April. 2026.gov.ukRead: full text
  41. GOV.UK. Launch of clinical trial reforms. 27 April. 2026.gov.ukRead: full text
  42. GOV.UK. UK life sciences attracts £3bn investment, creating jobs and faster patient treatments (Life Sciences Sector Plan: one year on). 9 July. 2026.gov.ukRead: full text
  43. Grant Witness. NIH weekly report, 12 October 2026. 2026.grantwitness.orgRead: full text
  44. Health Affairs Forefront. Unpacking the Supreme Court's decision over NIH funding. 2025.healthaffairs.orgRead: full text
  45. Health and Care Research Wales. Commercial study set up times reduced by a third, according to new data. 27 October. 2023.healthandcareresearchwales.orgRead: full textCited here
  46. Health Policy Watch. NIH-funded human trials outside US get temporary funding reprieve. 2025.healthpolicy-watch.newsRead: full text
  47. Health Research Authority. New National Contract Value Review data (bulletin). 23 May. 2023.content.govdelivery.comRead: full textCited here
  48. Health Research Authority. Our response to the Life Sciences Sector Plan. 2025.hra.nhs.ukRead: full text
  49. Health Research Authority. Research applications in the UK reviewed faster than ever in 2025. 2026.hra.nhs.ukRead: full text
  50. Health Research Authority. New UK clinical trials regulations now in force. April. 2026.hra.nhs.ukRead: full text
  51. Holland & Knight. The NIH-proposed 15 percent indirect cost rate cap is out (for now). January. 2026.hklaw.comRead: full text
  52. ICEX Invest in Spain. Spain, European leader in clinical drug research (AEMPS 2024 data). 2025.investinspain.orgRead: full text
  53. INFARMA and POLCRO. Industry clinical trials in Poland: global environmental scan and progress review through 2024 (local text copy). 2025.infarma.plRead: full text
  54. INFARMA, GCPpl, and POLCRO. Industry clinical trials in Poland: possibilities to increase number and scope of trials in Poland (LongTaal site-productivity and start-up benchmarks). 2021.infarma.plRead: full textAlso in chapter 8Cited here
  55. Inside Health Policy. Diversity Action Plan guidance, other deleted documents restored. February. 2025.insidehealthpolicy.comRead: full text
  56. IQVIA for EFPIA and Vaccines Europe. Assessing the clinical trial ecosystem in Europe: final report. August to October. 2024.efpia.euRead: full textAlso in chapter 6, chapter 8Cited here
  57. IQVIA Institute. Global R&D Trends 2026 (page). 25 March. 2026.iqvia.comRead: abstract
  58. Journal of Pharmaceutical Policy and Practice (PMC13270869). A mixed-methods evaluation of the quantitative and perceived impact of Brexit on UK oncology clinical trial initiation between 2011 and 2020. 2026.pmc.ncbi.nlm.nih.govRead: full text
  59. KFF. Health provisions in the 2025 federal budget reconciliation law. 2025.kff.orgRead: full text
  60. Medical Research Agency (ABM). English site. 2025.abm.gov.plRead: index only
  61. Medical Research Agency (PMC11699205). Medical Research Agency: 5 years of reshaping the clinical trials ecosystem in Poland. 2024/25. 2024.pmc.ncbi.nlm.nih.govRead: full text
  62. Medidata. COVID-19 and Clinical Trials: The Medidata Perspective, Release 9.0 (local text copy). 21 September. 2020.medidata.comRead: full textAlso in chapter 7, chapter 8Cited here
  63. Medizinforschungsgesetz, Bundesgesetzblatt 2024 I Nr. 324 (23 October 2024, promulgated 29 October 2024). 2024.recht.bund.deRead: full text
  64. National Cancer Institute. Insurance coverage and clinical trials. 2025.cancer.govRead: full text
  65. National Health Executive. Commercial study set-up process over 100 days quicker thanks to National Contract Value Review. 2023.nationalhealthexecutive.comRead: full text
  66. National Health Executive. NIHR investment launches UK-wide commercial research delivery network. 1 September. 2025.nationalhealthexecutive.comRead: full text
  67. Nature Reviews Drug Discovery. Benchmarking recruitment rates for phase III trials (supplementary information). 2024.doi.orgRead: full textAlso in chapter 8Cited here
  68. NHS England. Increasing research activity in the NHS (long read). 2025.england.nhs.ukRead: full text
  69. NHS England, Accelerated Access Collaborative. National Contract Value Review. 2025.england.nhs.ukRead: full text
  70. NIHR. NIHR issues final update on implementation of the Restart Framework. 2021.nihr.ac.ukRead: index only
  71. NIHR. Commercial study set up times reduced by a third. October. 2023.nihr.ac.ukRead: index onlyAlso in chapter 8
  72. NIHR. New NIHR Research Delivery Network to deliver key government priority projects; and RDN, About us. 2024.nihr.ac.ukRead: full text
  73. pharmaphorum. ABPI says UK clinical trials sector 'improving'. 17 November. 2023.pharmaphorum.comRead: full text
  74. PLoS ONE (PMC8407556). Impacts of COVID-19 on clinical research in the UK: a multi-method qualitative case study. 2021.pmc.ncbi.nlm.nih.govRead: full text
  75. PMC11963400. Advocating for collaboration among key partners to promote diversity in clinical studies amid policy challenges in the USA. 2025.pmc.ncbi.nlm.nih.govRead: full text
  76. RAPS. EU regulators set targets to promote European clinical trials; and Pharmaceutical Technology. New targets for clinical trials in the European Union. 2026.raps.orgRead: index only
  77. RAPS Regulatory Focus. Former FDA officials, experts decry HHS staff cuts. 31 March. 2025.raps.orgRead: full text
  78. Real Decreto 1090/2015, de 4 de diciembre, por el que se regulan los ensayos clínicos con medicamentos (BOE 24 December 2015; in force 13 January 2016). 2015.boe.esRead: full text
  79. Science. NIH funding policy deals new blow to HIV-related trial networks. 2025.science.orgRead: index only
  80. SCOTUSblog. Supreme Court allows Trump administration to terminate $783 million in NIH grants linked to DEI initiatives. 21 August. 2025.scotusblog.comRead: full text
  81. STAT. NIH halts funding for new projects with foreign collaborators, citing national security concerns. 1 May. 2025.statnews.comRead: full text
  82. STAT. NIH funding survey shows sizable impact of foreign subaward ban. 27 March. 2026.statnews.comRead: full text
  83. The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025, SI 2025/538, and explanatory memorandum. 2025.legislation.gov.ukRead: full text
  84. The Pharmaceutical Journal. Participation in commercial clinical trials falls for fourth year in a row, finds ABPI. 3 December. 2025.pharmaceutical-journal.comRead: full text
  85. The White House. Restriction on entry of certain nonimmigrant workers (proclamation). 19 September. 2025.whitehouse.govRead: full text
  86. The White House. Delivering most-favored-nation prescription drug pricing to American patients (Executive Order 14297). 12 May. 2025.whitehouse.govRead: full text
  87. Ustawa z dnia 9 marca 2023 r. o badaniach klinicznych produktów leczniczych stosowanych u ludzi (Dz.U. 2023 poz. 605). 2023.eli.gov.plRead: index only
  88. Wellcome. Regulation of clinical trials: Brexit and beyond. 2019.wellcome.orgRead: index only
  89. Wikipedia. Tariffs in the second Trump administration (secondary; pharmaceuticals section; page carries a verification notice). 2025.en.wikipedia.orgRead: full text
  90. Wikipedia. Biosecure Act (secondary; cites Congress.gov, Ropes & Gray, National Law Review January 2026). 2026.en.wikipedia.orgRead: full text
  91. Wikipedia. Advisory Committee on Immunization Practices (secondary; cites ABC News, NYT, Reuters, CDC charter, AP). 2026.en.wikipedia.orgRead: full text
  92. Wikipedia (French). Comité de protection des personnes (secondary; decree of 16 November 2016, 39 CPPs, 2022 reform). 2025.fr.wikipedia.orgRead: full textCited here
  93. Wikipedia (German). Medizinforschungsgesetz (secondary; cites BGBl, BMG, and press sources). 2025.de.wikipedia.orgRead: full text
  94. Wiley Rein. Update: federal judge blocks NIH cap on indirect rates for grants. 2025.wiley.lawRead: full text

Chapter 6 Countries and policy: India, Turkey, and the rest of the world

  1. Al Jeraisy M, Turgonyi E, Misik V, Alaskar A. Bridging the clinical trial gap in Saudi Arabia: a multi-stakeholder conference-based consensus on strategic initiatives for global competitiveness and patient inclusion. Saudi Pharmaceutical Journal 34(4):44. 2026.pmc.ncbi.nlm.nih.govRead: full text
  2. AusBiotech and Biotech Dispatch. AusBiotech welcomes $13.6 million investment to strengthen clinical trials. 6 October. 2025.biotechdispatch.com.auRead: full text
  3. Axios. Pharma fallout from Iran war won't end with ceasefire. 9 April. 2026.axios.comRead: index only (search-level; the site returned 403)
  4. Barnes M, Flaherty J, Caron M, Naqvee A, Bierer B. The evolving regulatory landscape for clinical trials in India. Food and Drug Law Journal 73:601. 2018.law.yale.eduRead: full textCited here
  5. Beaney A. Israel prepared to keep clinical trials running during war. Clinical Trials Arena. 11 October. 2023.clinicaltrialsarena.comRead: full text
  6. Beaney A. Iran-Israel conflict disrupts trial initiations. Clinical Trials Arena (GlobalData). 24 July. 2025.clinicaltrialsarena.comRead: full text
  7. Beaney A. OCT West Coast 2025: China surpasses US for annual number of clinical trials. Clinical Trials Arena. 12 February. 2025.clinicaltrialsarena.comRead: full text
  8. Beaney A. Data shows 6.7% of global clinical trials impacted by Middle East disruption. Clinical Trials Arena. 2 April. 2026.clinicaltrialsarena.comRead: full text
  9. Bhatt A. International regulatory agencies: Indian clinical trials. Perspectives in Clinical Research 2(1):41. 2011.pmc.ncbi.nlm.nih.govRead: full text
  10. Bhide S, Patil S, Sohal A, et al. Investigator knowledge, awareness, and registrations of academic clinical trials with the Clinical Trial Registry of India. Perspectives in Clinical Research 14(4):187–193. 2023.pmc.ncbi.nlm.nih.govRead: full text
  11. Bhide SS, Tadavi FM, Maurya MR, Bhojne SK, Chandrakar P. Assessment of clinical trials registered at clinical trial registry of India over past decade: an audit. International Journal of Clinical Trials 3(4):238–243. 2016.ijclinicaltrials.comRead: full text
  12. Castañeda R. As Russia's clinical trials sector falls, Ukraine rebuilds. Clinical Trials Arena. 23 August. 2022.clinicaltrialsarena.comRead: full text
  13. Castañeda R. Clinical trials in Russia: drug development pipeline at risk. Clinical Trials Arena. 7 March. 2022.clinicaltrialsarena.comRead: full text
  14. Chawan VS, Gawand KV, Phatak AM. Impact of new regulations on clinical trials in India. International Journal of Clinical Trials 2(3):56–58. 2015.ijclinicaltrials.comRead: full text
  15. Clinical Trials Arena. UAE positions itself as a regional leader and a clinical trial hub.clinicaltrialsarena.comRead: index only (search-level)
  16. Clinical Trials Arena (GlobalData). Canada accounts for 3.8% share of global clinical trial activity in 2021. 1 April. 2022.clinicaltrialsarena.comRead: full text
  17. Copelyn J. U.S. pulls funding for South African medical research. Spotlight and GroundUp, via AllAfrica. 9 May. 2025.allafrica.comRead: full text
  18. Cullinan K. NIH cuts to South Africa will cause global loss of TB and HIV research capacity. Health Policy Watch. 15 May. 2025.healthpolicy-watch.newsRead: full text
  19. Eglovitch JS. FDA turns attention to data integrity lapses at testing sites in new guidance. RAPS Regulatory Focus. 2 April. 2024.raps.orgRead: full text
  20. EMA Biostatistics Working Party. Points to consider on the impact of the war in Ukraine on methodological aspects of ongoing clinical trials (EMA/214249/2022). 13 April. 2022.ema.europa.euRead: full text
  21. European Business Association. Clinical trials in Ukraine 2022–2025: recovery dynamics and future outlook.eba.com.uaRead: index only (search-level; the page returned 403)
  22. European Medicines Agency. Synchron Research Services, Article 31 referral, Annex II: scientific conclusions. 2022.ema.europa.euRead: full text
  23. Farooq U. Lira crash slams Turkey's factories, farmers and retailers. Al Jazeera. 3 December. 2021.aljazeera.comRead: full textCited here
  24. Federal Financial Relations. Commonwealth FFA for Encouraging More Clinical Trials to Australia, Queensland schedule. March. 2026.federalfinancialrelations.gov.auRead: full text
  25. Fierce Biotech. FDA asks pharmas to repeat studies done at 2 Indian CROs due to data integrity issues. 2021.fiercebiotech.comRead: index only (search-level; Synapse Labs details not verified)
  26. Fultinavičiūtė U, Maragkou I. A year of Russia's war in Ukraine: who is winning the battle on clinical trials? Clinical Trials Arena. 23 February. 2023.clinicaltrialsarena.comRead: full text
  27. Garabetyan E. La investigación médica crece: Anmat ya aprobó más ensayos clínicos que durante todo 2025. Perfil. 15 October. 2026.perfil.comRead: full text
  28. Goldberg P, Tracey A. In a 14:1 vote, ODAC nixes a PD-1 drug developed in China; data not generalizable to U.S. population. The Cancer Letter. 11 February. 2022.cancerletter.comRead: full text
  29. Greenberg Traurig. BIOSECURE Act update: court enjoins WuXi AppTec's 1260H designation, but strategic and compliance clocks keep running. September. 2026.gtlaw.comRead: index only (search-level)
  30. Gulf News. Argentina inflation seen at 126.4% in 2023, central bank poll shows. 2023.gulfnews.comRead: index only (search-level)
  31. Gupta YK, Kumar BD. Clinical trials and evolving regulatory science in India. Indian Journal of Pharmacology 46(6):575–578. 2014.pmc.ncbi.nlm.nih.govRead: full text
  32. Hasanzadeh L. Navigating medicine pricing in Türkiye: the pharmaceutical euro exchange rate. Pharmaceutical Technology (GlobalData). 3 December. 2024.pharmaceutical-technology.comRead: full textCited here
  33. Holland & Knight. WuXi AppTec added to DOW's 1260H list: the BIOSECURE Act clock is running. June. 2026.hklaw.comRead: index only (search-level)
  34. Human L. World's largest research funder lifts ban on South Africa. GroundUp and Spotlight. 24 August. 2026.groundup.newsRead: full text
  35. Ilancheran M. Measuring the impact of reforms on India's clinical trial environment. Clinical Leader. 12 October. 2017.clinicalleader.comRead: full text
  36. Innovative Medicines Canada. Clinical trials in Canada 2023: research note. 2023.innovativemedicines.caRead: full text
  37. Innovative Medicines Canada. Clinical trials in Canada: research note, June 2025. 2025.innovativemedicines.caRead: full text
  38. Inter-Governmental Policy Reform Group. Newsletter. 20 May. 2026.australianclinicaltrials.gov.auRead: index only (search-level; the site was unreachable)
  39. IQVIA for AİFD. Benefits of a clinical research strategy for Turkey. September. 2020.aifd.org.trRead: full textCited here
  40. IQVIA for the EFPIA Oncology Platform. The impact of the war in Ukraine on oncology patients. 2022–.efpia.euRead: full text
  41. IQVIA Laboratories. Delivering excellence in China.labs.iqvia.comRead: full text
  42. ITIF. Fact of the Week: China has surpassed the US in the number of drug clinical trials, with 1,100 more trials listed. 9 June. 2025.itif.orgRead: index only (search-level)
  43. Jeong M. Korea ranks 5th in global share of pharmaceutical clinical trials. Korea Biomedical Review. 14 April. 2023.The original link no longer worksRead: full text
  44. Kachkovska V, Anderson EE. Global pharmaceutical companies' obligations to restart clinical research in Ukraine. American Journal of Bioethics 25(4):32–35. 2025.pmc.ncbi.nlm.nih.govRead: full text
  45. Kawakita Y, Matsumoto K, Hirano M, et al. Reimagining early-phase clinical development in Japan: from regulatory obligation to global acceleration. Clinical and Translational Science 19(1):e70467. 2026.pmc.ncbi.nlm.nih.govRead: full text
  46. Kent C. Indian health ministry fast-tracks drug approvals with new clinical trial legislation. Clinical Trials Arena. 26 March. 2019.clinicaltrialsarena.comRead: full text
  47. KoNECT. Start with Korea. May. 2025.konect.or.krRead: full text
  48. Koyuncu O, Gursoz H, Alkan A, et al. Evaluation of the performance of the Turkish regulatory agency: recommendations for improved patients' access to medicines. Frontiers in Pharmacology 10:1557. 2020.frontiersin.orgRead: full textCited here
  49. Kwak S. Health ministry moves to tackle decline in Korea's clinical trials. Korea Biomedical Review. 10 July. 2025.The original link no longer worksRead: full text
  50. Latham & Watkins. BIOSECURE Act becomes law limiting grants with biotechnology companies of concern. 31 December. 2025.lw.comRead: full text
  51. Lawal S. African researchers are working to cure HIV, but US aid cuts are in the way. Al Jazeera. 1 May. 2025.aljazeera.comRead: full text
  52. MacPhail K. Q&A: How Trump's USAID freeze halted the effort to develop an effective HIV vaccine in Africa. STAT. 26 February. 2025.statnews.comRead: full text
  53. Martinez-Clark JG. Mexico is becoming Latin America's clinical trial powerhouse, while Colombia falls behind. bioaccess blog (vendor). 14 March. 2026.bioaccessla.comRead: full text
  54. Mashaki Ceyhan E, Gürsöz H, Alkan A, et al. The Turkish Medicines and Medical Devices Agency: comparison of its registration process with Australia, Canada, Saudi Arabia, and Singapore. Frontiers in Pharmacology 9:9. 2018.frontiersin.orgRead: full text
  55. MASSİAD. TİTCK Klinik Araştırma Etik Kurulları Hakkında (on TİTCK clinical-research ethics committees). 2 June. 2023.massiad.org.trRead: full text
  56. McKenzie H. CRO data integrity concerns have pharma companies scrambling to repeat bioequivalence studies. BioSpace. 29 September. 2021.biospace.comRead: full text
  57. Misik V. The impact of the Russia–Ukraine war on clinical trials. Clinical Leader. 7 September. 2022.clinicalleader.comRead: full text
  58. Nathan A. War fractures emerging clinical trial infrastructure in the Middle East. The Scientist. 2026.the-scientist.comRead: full textAlso in chapter 7
  59. NIAID ClinRegs. India country profile (updates to 2026). 2026.clinregs.niaid.nih.govRead: full text
  60. NIAID ClinRegs. China country profile (updates to 2026). 2026.clinregs.niaid.nih.govRead: full text
  61. NIAID ClinRegs. Brazil country profile (updates to 2026). 2026.clinregs.niaid.nih.govRead: full text
  62. NIAID ClinRegs. Mexico country profile (updates to 2026). 2026.clinregs.niaid.nih.govRead: full text
  63. NIAID ClinRegs. Canada country profile (updates to 2026). 2026.clinregs.niaid.nih.govRead: full text
  64. Ontario Leadership Table (Clinical Trials Ontario). Position paper. November. 2023.ctontario.caRead: full text
  65. Outsourcing-Pharma. Finland, Brazil & Mexico top per site recruitment; visualisation (EMA 2005–2009 data). 30 November. 2010.web.archive.orgRead: index only (search-level; the page now returns 410)Cited here
  66. Pacific Bridge Medical. Japan Phase 1 drug clinical trials no longer needed for global clinical trials. 29 September. 2023.pacificbridgemedical.comRead: full text
  67. Phesi. Almost half of Ukraine's clinical trials to find new therapies are still recruiting patients despite ongoing conflict. October. 2022.phesi.comRead: full textAlso in chapter 8Cited here
  68. Phesi. New Phesi data shows 6.7% of global clinical trials impacted by Middle East disruption. 1 April. 2026.phesi.comRead: full textAlso in chapter 7Cited here
  69. PMDA. PMDA Updates, July 2017 (ICH Assembly, Montreal, 27 May to 1 June 2017). 2017.pmda.go.jpRead: full text
  70. Presidência da República. Lei nº 14.874, de 28 de maio de 2024 (Brazil's clinical research law). 2024.planalto.gov.brRead: full text
  71. Ramírez Coronel M. Article in El Economista, 21 March 2021, republished by Salud y Fármacos. August. 2021.saludyfarmacos.orgRead: full text
  72. RAPS. Asia Regulatory Roundup: CFDA clampdown on clinical trial data. 17 November. 2015.raps.orgRead: full text
  73. Ravindranath AG, Benny A, Bhalla IS, Vaswani R, Saberwal G. Clinical trial registration in India: 12% of drug regulatory trials are not registered, as required by law. Health Research Policy and Systems 23:19. 2025.link.springer.comRead: full text
  74. SAHPRA. Clinical trials.sahpra.org.zaRead: full text
  75. SAHPRA. Backlog.sahpra.org.zaRead: full text
  76. Science. NIH halts more collaborations with South Africa on HIV/AIDS trials (2025),. 2025.science.orgRead: index only (search-level; the site returned 403)
  77. Shiga K, Shibata T, Miyata T. Evaluation of drug lag and drug loss in Japan: participation in global phase III oncology trials. International Journal of Clinical Oncology 30(6):1109–1117. 2025.pmc.ncbi.nlm.nih.govRead: full text
  78. Smooth Drug Development. Clinical trials in Turkey (vendor page, data to 2023). 2023.smoothdd.comRead: full text
  79. State Expert Center of the Ministry of Health of Ukraine. Key trends in the development of clinical trials of medicinal products in Ukraine in 2025. 17 February. 2026.dec.gov.uaRead: full text
  80. Stockholm Center for Freedom (advocacy group). Survey shows purge of over 8,000 academics leads to 28 pct decrease in scientific research in Turkey.The original link no longer worksRead: index only (search-level)
  81. Tampal N (US FDA, Office of Generic Drugs). Impact assessment of FDA's data integrity notifications to sponsors. SBIA Generic Drugs Forum, 12–13 April. 2023.fda.govRead: full text
  82. The Pathologist. Middle East conflict hits medical research. April. 2026.thepathologist.comRead: full textAlso in chapter 7
  83. The Pharma Letter. Russia faced with decline of clinical trials of medicines (Vademecum and Kommersant data on 2022 permits). 2022.thepharmaletter.comRead: index only (search-level)
  84. The Pharma Letter. Foreign CROs suspending participating in clinical trials in Russia (ACTO data, first half of 2023). 2023.thepharmaletter.comRead: index only (search-level)
  85. The Pharma Letter. Iran war disrupts nearly 8,000 clinical trial sites. 2 April. 2026.thepharmaletter.comRead: full text, except the per-country site counts (search-level)
  86. The Tokyo Foundation. Addressing Japan's "drug loss, drug lag": an analysis and proposals for revamp. 6 September. 2024.tokyofoundation.orgRead: full text
  87. Thomson Reuters. Overcoming clinical challenges in BRIC markets: a white paper. April 2014. No public URL recorded; cited via reference 1. 2014.No link recordedRead: index only (not retrieved)
  88. TİTCK. 2021 Yılı İdare Faaliyet Raporu (activity report for 2021). 2022.titck.gov.trRead: full text
  89. TİTCK. 2022 Yılı İdare Faaliyet Raporu (activity report for 2022). 27 February. 2023.titck.gov.trRead: full text
  90. TİTCK. Klinik Araştırma Taraflarının Dikkatine (notice to clinical trial parties). 3 March. 2023.titck.gov.trRead: full text
  91. TİTCK. 2023 Yılı İdare Faaliyet Raporu (activity report for 2023). 4 March. 2024.titck.gov.trRead: full textCited here
  92. TİTCK. 2024 Yılı İdare Faaliyet Raporu (activity report for 2024). 28 February. 2025.titck.gov.trRead: full textCited here
  93. TİTCK. Klinik Araştırma İstatistikleri (2019–2025), presentation, linked from the TİTCK clinical-trials page. 2026.titck.gov.trRead: full text
  94. TİTCK. 2025 Yılı İdare Faaliyet Raporu (activity report for 2025). 27 February. 2026.titck.gov.trRead: full textCited here
  95. TİTCK Klinik Araştırmalar Dairesi Başkanlığı. Deprem Afeti Nedeniyle Klinik Araştırmalarda Alınacak Tedbirler (measures to be taken in clinical trials due to the earthquake disaster), V1.0. 28 February. 2023.titck.gov.trRead: full textCited here
  96. TÜBİTAK. 2023 Deprem Bölgesi Özel Çağrısı: TEKNOÇABA Açıldı (earthquake-zone special call, listing the 11 provinces). 2023.tubitak.gov.trRead: index only (search-level)
  97. Turkish Minute (reporting BBC Turkish). Cancer drug shortage in Turkey raises treatment concerns. 30 April. 2026.turkishminute.comRead: full textCited here
  98. UNHCR Türkiye. Provincial breakdown of Syrian refugees in Türkiye, as of 5 October 2023. 2023.data.unhcr.orgRead: full text
  99. University of Augsburg repository (authors not recorded). The impact of decree laws on the performance of Turkish academic family physicians: a repeated cross-sectional study.opus.bibliothek.uni-augsburg.deRead: index only (search-level)
  100. US FDA. Considerations for the conduct of clinical trials of medical products during major disruptions due to disasters and public health emergencies. Final guidance. September. 2023.fda.govRead: full textAlso in chapter 7
  101. Van Beusekom M. US cuts to HIV programs in sub-Saharan Africa pose global risk, experts say. CIDRAP. January. 2026.cidrap.umn.eduRead: full text
  102. Weinreb G. Clinical trials in Israel decline sharply. Globes. 18 June. 2024.en.globes.co.ilRead: full textAlso in chapter 7
  103. Xu L, Gao H, Kaitin KI, Shao L. Reforming China's drug regulatory system. Nature Reviews Drug Discovery 17:858–859. 2018.nature.comRead: full text
  104. Zawya. Saudi's SFDA: 83% growth in clinical research for biotechnology products in 2025,. 2025.zawya.comRead: index only (search-level; the SFDA page returned 403)

Chapter 7 Shocks: pandemics, conflict, disasters, and the early-warning problem

  1. AACI Clinical Trials Office Staff Retention Task Force. 2022 to 2023 CTO Staff Retention Surveys. 2023.aaci-cancer.orgRead: full textCited here
  2. ACLED. About ACLED.acleddata.comRead: full text
  3. Advarra. 2025 Workforce Development Survey Report. 2025.resource.advarra.comRead: full textCited here
  4. AEMPS. Medidas excepcionales aplicables a los ensayos clínicos para gestionar los problemas derivados de la emergencia por COVID-19 (16 March 2020, updated to 1 July 2020). 2020.aemps.gob.esRead: full text
  5. Africa.com. Sudan's ongoing conflict has devastated key medical research infrastructure (reporting The Guardian, 8 May 2025). 2025.africa.comRead: full text
  6. Aguero D, Allen. Weathering The Storm: Commentary on the Hurricane Helene IV Fluid Shortage. Journal of Pediatric Pharmacology and Therapeutics. 2024.doi.orgRead: full text
  7. Almagro P et al. Seasonality, ambient temperatures and hospitalizations for acute exacerbation of COPD: a population-based study in a metropolitan area. International Journal of COPD. 2015.doi.orgRead: full text
  8. American Hospital Association. Change Healthcare Cyberattack Underscores Urgent Need to Strengthen Cyber Preparedness. 2024.aha.orgRead: full text
  9. American Hospital Association. CrowdStrike Technology Outage Causing Global Disruption, Including Impacts on Hospitals (advisory, 19 July 2024). 2024.aha.orgRead: full text
  10. AONL, reporting MedPage Today on a JAMA Internal Medicine cross-sectional study (authors not retrieved). Thousands affected by cuts to NIH-funded clinical trials. 2025.aonl.orgRead: full textCited here
  11. Bakouny Z et al. Annals of Oncology 2022, reported in Healio, Cancer clinical trials recover from substantial disruption during COVID-19 pandemic. 2022.healio.comRead: full text (Healio report)
  12. BioSpace. Vor Bio Looks for Exit in Challenging Funding Environment; Lays Off 95% of Staff. 2025.biospace.comRead: index only
  13. Bitdefender Hot for Security. COVID-19 Vaccine Trials Slowed Down by a Ransomware Attack. 2020.bitdefender.comRead: index only
  14. BleepingComputer. Synnovis notifies of data breach after 2024 ransomware attack. 2025.bleepingcomputer.comRead: full text
  15. Borchert RJ et al. Impact of the junior doctors' industrial action on the efficiency of a radiology department. Clinical Radiology. 2025.europepmc.orgRead: abstractCited here
  16. Cancer Network. Hurricane-Hit Practice Offers Lessons in Disaster Planning.cancernetwork.comRead: index only
  17. Cancer Research Institute and IQVIA. Cancer Research Institute and IQVIA Uncover the Impact of COVID-19 Pandemic on Global Oncology Clinical Trials. 2020.cancerresearch.orgRead: full text
  18. Chief Scientist Office (Scotland). CSO Statement on guidance to protect research during a second wave of COVID-19 activity. 2020.cso.scot.nhs.ukRead: full textCited here
  19. Clinical Leader. When Clinical Trials Don't Stop For War. 2026.clinicalleader.comRead: full textCited here
  20. Clinical Research News. In War-Torn Ukraine, Clinical Trials Trudge Along. 2022.clinicalresearchnewsonline.comRead: full textCited here
  21. Clinical Trials Arena. Israel prepared to keep clinical trials running if country goes to war. 2023.clinicaltrialsarena.comRead: index only
  22. Clinical Trials Arena (GlobalData). Russia clinical trials fall as Ukraine rebuilds. 2022.clinicaltrialsarena.comRead: full textCited here
  23. CNN (Christensen J), republished by KEYT. Drug shortages' effects on cancer research may be felt for years to come. 2023.keyt.comRead: full textCited here
  24. Cyprus Mail. Junior doctors in England plan more strikes in fight for better pay. 2023.cyprus-mail.comRead: full text (Cyprus Mail); index only (Dark Daily)
  25. De Guzman RB et al. Lung cancer in Asia: the impact of climate change. EClinicalMedicine. 2024.europepmc.orgRead: full text
  26. Detoc M et al. Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic. Vaccine. 2020.europepmc.orgRead: full text
  27. DIA Global Forum. From COVID-19 Pandemic to War: Clinical Trial Industry Powers On Under Extreme Conditions. 2023.globalforum.diaglobal.orgRead: full textCited here
  28. EMA. Reflection paper on risk based quality management in clinical trials (EMA/269011/2013). 2013.ema.europa.euRead: full text
  29. EMA. Guidance to sponsors on how to manage clinical trials during the COVID-19 pandemic (EMA/141885/2020). 2020.ema.europa.euRead: full text
  30. EMA. Advice to sponsors on managing the impact of the war in Ukraine on clinical trials. 2022.ema.europa.euRead: full text
  31. European Commission, EMA and HMA. Guidance on the management of clinical trials during the COVID-19 (Coronavirus) pandemic, version 5 (copy hosted by EJP RD). 2022.ejprarediseases.orgRead: full text
  32. European Commission, HMA and EMA. Recommendation paper on decentralised elements in clinical trials, version 02 (supersedes December 2022). 2025.health.ec.europa.euRead: full text
  33. Faegre Drinker. FDA Updates Conduct of Clinical Trials During the COVID-19 Emergency (history of the 18 March 2020 FDA guidance and its updates). 2020.faegredrinker.comRead: full text
  34. Fierce Biotech. Goldfinch Bio falls from the sky after failing to find a path forward for kidney treatments. 2023.fiercebiotech.comRead: index only
  35. Fortune. Pfizer pauses clinical trials in Russia. 2022.fortune.comRead: full text
  36. Freyr Solutions. FDA issues final guidance on conducting clinical trials with decentralized elements on 17th Sept 2024. 2024.freyrsolutions.comRead: full text
  37. Garner A et al. Evaluating the impact of NHS strikes on patient flow through emergency departments. Emergency Medicine Journal. 2026.europepmc.orgRead: abstract
  38. GlobalData. 67.3% of clinical trials disrupted by COVID-19 are due to enrollment suspension. 2020.globaldata.comRead: full text
  39. GlobalData. COVID-19 continues to disrupt clinical trials, with 69.9% of disruptions due to the suspension of enrolment. 2020.globaldata.comRead: index only
  40. GlobalData. COVID-19 disrupted clinical trials with suspended enrollment more likely to resume. 2020.globaldata.comRead: full text
  41. GOV.UK. Foreign travel advice.gov.ukRead: full text
  42. Haidich AB, Ioannidis JP. Determinants of patient recruitment in a multicenter clinical trials group: trends, seasonality and the effect of large studies. BMC Medical Research Methodology. 2001.doi.orgRead: abstractCited here
  43. Hussain R et al. Disruption of normal saline supply chain due to a disaster. Frontiers in Medicine. 2025.doi.orgRead: full text
  44. ICH. E8(R1) General Considerations for Clinical Studies, Step 4, adopted 6 October 2021. 2021.database.ich.orgRead: full textAlso in review note 01
  45. ICH. E6(R3) Good Clinical Practice, Step 4, adopted 6 January 2025. 2025.database.ich.orgRead: full textAlso in review note 01, review note 03
  46. ICON plc. ICH GCP E6(R3): transformative updates make Good Clinical Practice better. 2025.iconplc.comRead: full text
  47. IFRC. Türkiye Earthquake: IFRC Disaster Brief. 2023.ifrc.orgRead: full textCited here
  48. Infosecurity Magazine. Ransomware Disrupts COVID-19 Medical Trials (reporting The New York Times). 2020.infosecurity-magazine.comRead: full text
  49. IQVIA Holdings. Q2 2020 earnings call transcript (The Motley Fool). 2020.fool.comRead: full text
  50. ISID. About ProMED.promedmail.orgRead: full text
  51. Jenkins CR et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal. 2012.doi.orgRead: full text
  52. Kalema AG et al. Building resilience when disaster strikes: adapting clinical trials in critical illness recovery. Annals of the American Thoracic Society. 2026.europepmc.orgRead: full text
  53. Kozlov M. NIH grant cuts will axe clinical trials abroad, and could leave thousands without care. Nature. 2025.doi.orgRead: full text
  54. Lab News (Phesi data). Ukraine conflict leaves a hole in clinical trials enrolment in region. 2022.labnews.co.ukRead: full textCited here
  55. Lab News (Phesi data). Putin invasion has seen loss of two out of three clinical investigator sites in Ukraine and Russia. 2023.labnews.co.ukRead: full textCited here
  56. Lafarga Previdi I et al. Lessons Learned: Community Engagement in Emergencies in Puerto Rico. Disaster Medicine and Public Health Preparedness. 2023.europepmc.orgRead: full text
  57. Mayo Clinic, In the Loop. In the Wake of Hurricane Maria, Mayo Clinic Clinical Trials Carry On in Puerto Rico. 2017.intheloop.mayoclinic.orgRead: full text
  58. McDuffie R, Summerson J, Reilly P, Blackwell C, Goff D, Kimel AR, Crago L, Fonseca V. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial and Hurricane Katrina: lessons for managing clinical trials during and after a natural disaster. Contemporary Clinical Trials. 2008.pmc.ncbi.nlm.nih.govRead: abstract
  59. MedCity News. What the Great Resignation means for clinical research (OpenClinica survey; anecdotal). 2022.medcitynews.comRead: full text
  60. Médecins Sans Frontières. Ebola drug trial in Liberia halted. 2015.msf.orgRead: index only
  61. Médecins Sans Frontières. Sudan (country page, accessed October 2026). 2026.msf.orgRead: full text
  62. Medical Laboratory Observer. Labcorp Systems, Quest Diagnostics, Impacted by CrowdStrike-Related Outage. 2024.mlo-online.comRead: index only
  63. Medidata. COVID-19 and Clinical Trials: The Medidata Perspective, Release 6.0. 2020.medidata.comRead: full text (table reconstructed from the PDF text layer)Cited here
  64. Medidata. COVID-19 and Clinical Trials: The Medidata Perspective, Release 2.0 (cited in the research note as S1a). 2020.medidata.comRead: full textAlso in chapter 8Cited here
  65. Meltzer GY et al. Aspirin and Preterm Birth Among Pregnant People With Increased Heat Exposure: Secondary Analysis of a Randomized Clinical Trial. JAMA Network Open. 2026.europepmc.orgRead: full text
  66. MHRA. Managing clinical trials during Coronavirus (COVID-19), first published 19 March 2020, last updated 16 November 2021. 2021.gov.ukRead: full text
  67. National Audit Office. Investigation: WannaCry cyber attack and the NHS. 2017.nao.org.ukRead: full text
  68. National Hurricane Center. Tropical Cyclone Report: Hurricane Katrina, 23 to 30 August 2005. 2005.nhc.noaa.govRead: full text
  69. National Hurricane Center. Tropical Cyclone Report: Hurricane Maria, 16 to 30 September 2017. 2017.nhc.noaa.govRead: full text
  70. News is my Business. Yale validates PRCCI's readiness after Hurricane María. 2018.newsismybusiness.comRead: full text
  71. NHS England. Synnovis cyber incident: public questions and answers. 2024.england.nhs.ukRead: full text
  72. NHS England London. Update on cyber incident: clinical impact in south east London, Thursday 8 August. 2024.england.nhs.ukRead: index only
  73. OncLive. Effects of Cancer Drug Shortages Linger as New Survey Results Show Impacts on Clinical Trials (NCCN survey). 2024.onclive.comRead: full textCited here
  74. Outsourcing-Pharma. CROs report on Japan quake impact. 2011.web.archive.orgRead: index only
  75. Pharmaceutical Technology. Portage mulls company closure, pauses enrolment for lead clinical programme. 2024.pharmaceutical-technology.comRead: full text
  76. Pharmaceutical Technology (GlobalData). Covid-19 pandemic disrupted more than 1,200 clinical trials: data. 2021.pharmaceutical-technology.comRead: full text
  77. Pouncey A. Hurricane Katrina: What Have We Learned? Applied Clinical Trials. 2006.appliedclinicaltrialsonline.comRead: full text
  78. Premier Research. Seasonality: a factor for successful patient recruitment (anecdotal).premier-research.comRead: full text
  79. Relias Media. When disaster strikes: In Katrina's wake, IRBs struggle to regroup.reliasmedia.comRead: index only
  80. Shelford Group. Shelford CEOs statement on industrial action. 2023.shelfordgroup.orgRead: full text
  81. Sidley Austin. US FDA's Adoption of ICH E6(R3) Good Clinical Practice: Key Takeaways for Sponsors and Investigators. 2025.sidley.comRead: full text
  82. Spectrum Science. Clinical Trial Experience (recruitment campaign data; anecdotal).spectrumscience.comRead: full text
  83. Sun G et al. Crisis of the Clinical Trials Staff Attrition After the COVID-19 Pandemic. JCO Oncology Practice. 2023.pmc.ncbi.nlm.nih.govRead: full textCited here
  84. The ASCO Post. New Survey Finds Cancer Drug Shortage Management Remains a Moving Target. 2024.ascopost.comRead: full textCited here
  85. The GDELT Project. Home page.gdeltproject.orgRead: full text
  86. The Pharma Letter. Global drugmakers refusing to test new drugs in Russia. 2022.thepharmaletter.comRead: index only
  87. The Transmitter. Biotech downturn hurts companies targeting autism-linked conditions. 2023.thetransmitter.orgRead: index only
  88. The White House (archived). Remarks by President Biden Providing an Update on Russia and Ukraine. 2022.bidenwhitehouse.archives.govRead: full text
  89. Tully JL et al. Patient Care Technology Disruptions Associated With the CrowdStrike Outage. JAMA Network Open. 2025.doi.orgRead: full text
  90. UN OCHA ReliefWeb. ReliefWeb API documentation.apidoc.reliefweb.intRead: full text
  91. Unger JM et al. Cancer Clinical Trial Participation at the 1-Year Anniversary of the Outbreak of the COVID-19 Pandemic. JAMA Network Open. 2021.doi.orgRead: full textCited here
  92. Waterhouse DM et al. Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey. JCO Oncology Practice. 2020.doi.orgRead: full text
  93. Webster N, Vardy J, Wise-Rankovic A (INC Research). Enrollment Patterns: Implications for CNS Clinical Trials (ISCTM Autumn 2015 poster). 2015.isctm.orgRead: full textCited here
  94. WHO. Listings of WHO's response to COVID-19. 2020.who.intRead: full textCited here
  95. WHO. Disease Outbreak News.who.intRead: full text
  96. WHO Regional Office for Europe. Türkiye earthquake: external situation report no. 2, 20 to 26 February. 2023.who.intRead: index only (metadata; PDF not retrieved)
  97. Williams RJ, Tse T, DiPiazza K, Zarin DA. Terminated Trials in the ClinicalTrials.gov Results Database: Evaluation of Availability of Primary Outcome Data and Reasons for Termination. PLOS ONE. 2015.journals.plos.orgRead: full textAlso in review note 02Cited here
  98. Wyatt S et al. Industrial action and emergency department attendances in England, 2022 to 2024: a retrospective multicentre causal mediation analysis. Journal of the Royal Society of Medicine. 2026.europepmc.orgRead: abstractCited here
  99. Yamamoto K et al. Loss of participation among evacuees aged 20 to 37 years in the disaster cohort study after the Great East Japan Earthquake. Scientific Reports. 2022.europepmc.orgRead: full textCited here

Chapter 8 The numbers behind the planner: start-up times, screen failure, rates, and site variation

  1. Anisimov V, et al. Simulation of patient recruitment with gamma-distributed centre rates (arXiv 2411.17393). 2024.arxiv.orgRead: full textAlso in chapter 9Cited here
  2. Ascot; CASRAI. Vendor web pages giving practice estimates for trial start-up in Türkiye.No link recordedRead: index only
  3. BioPharma Dive. Trials active in Ukraine at the invasion and permanent stops in the first year. 2023.No link recordedRead: index only
  4. BioSpectrum India. Clinical trial numbers in India drop drastically. 2013.biospectrumindia.comRead: full text
  5. Boehringer Ingelheim. EMPEROR-Reduced poster: empagliflozin according to background diuretic use in HFrEF (Verma). 2023.The original link no longer worksRead: full text
  6. Brøgger-Mikkelsen M, et al. Recruitment performance of industry Phase III drug trials registered on ClinicalTrials.gov, 2012 to 2019. PLOS ONE. 2022.journals.plos.orgRead: full textCited here
  7. Chen, et al. Drop-out in 10,252 Phase III trials with results on ClinicalTrials.gov. British Journal of Clinical Pharmacology. 2025.doi.orgRead: abstractCited here
  8. CIDRAP, reporting JAMA Internal Medicine. NIH grant terminations disrupt hundreds of clinical trials, affecting more than 74,000 participants. 2025.cidrap.umn.eduRead: full text
  9. DAPA-HF trial disposition, slide deck (to be verified against the NEJM 2019 primary paper). 2019.No link recordedRead: index only
  10. Fierce Biotech. Thousands of clinical trial sites impacted by war with Iran, Phesi report. 2026.fiercebiotech.comRead: full text
  11. Friends of Cancer Research. Data-driven insights: fast to start, slow to scale, US oncology trial start-up in a global context. 2026.friendsofcancerresearch.orgRead: full textCited here
  12. Getz K, Tufts Center for the Study of Drug Development. Can recruitment and retention get any worse? Applied Clinical Trials. 2019.appliedclinicaltrialsonline.comRead: full textCited here
  13. GlobalData, via Pharmaceutical Technology. Enrolment rates in Brazilian trials by number of sites, 2001 to 2018. Year not recorded in the note. 2018.No link recordedRead: index only
  14. GOV.UK. UK clinical research delivery key performance indicators, data to March 2026. 2026.gov.ukRead: full textCited here
  15. Health Research Authority. Our performance: HRA and HCRW approval. 2025.hra.nhs.ukRead: full text
  16. Indian Journal of Pharmaceutical Education and Research. Article on the New Drugs and Clinical Trials Rules, 2019 (volume 53, issue 4s). 2019.ijper.orgRead: full textCited here
  17. Indian Pharma Post. Middle East disruption hits thousands of global clinical trials, Phesi warns. 2026.indianpharmapost.comRead: full text
  18. Infarma, with LongTaal data. Clinical trials in Poland, 2025 report. 2025.infarma.plRead: full textCited here
  19. JAMA Network Open. Recruitment status changes among 888 ongoing trials with Ukrainian sites in the year after the invasion. 2023.No link recordedRead: index only
  20. Kemmler G, et al. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs. Archives of General Psychiatry. 2005.jamanetwork.comRead: full text
  21. KMR Group. Realistic recruitment expectations require disease and geographic considerations. Applied Clinical Trials. 2013.appliedclinicaltrialsonline.comRead: full text
  22. Lab News, reporting Phesi. Growth in oncology recruiting sites, 2019 to 2024. 2024.The original link no longer worksRead: full text
  23. Letter on screened-not-randomised rates in the ILLUMINATE, SHINE, and SPARK COPD Phase III programmes (PubMed Central PMC5125986). 2016.pmc.ncbi.nlm.nih.govRead: full textCited here
  24. medRxiv preprint. Phase III oncology trial sites recruiting on ClinicalTrials.gov in July 2024: 1,281 trials and 6,634 unique facilities. 2026.medrxiv.orgRead: full text
  25. Minois N, et al. Poisson-gamma modelling of patient recruitment in IFM myeloma trials. Statistics in Medicine. 2017.chu-toulouse.frRead: full textAlso in chapter 9Cited here
  26. Mondaq. Recent developments in the healthcare sector (Türkiye). Year not recorded in the note.mondaq.comRead: full textCited here
  27. Moore TJ, et al. Estimated costs of 225 pivotal trials supporting FDA approvals, 2015 to 2017. BMJ Open. 2020.ebi.ac.ukRead: full textCited here
  28. PubMed Central article PMC8694703. Ethics committee approval times at 42 Indian sites in COVID-era trials. Year not recorded in the note.pmc.ncbi.nlm.nih.govRead: full textCited here
  29. Redacción Médica, reporting Farmaindustria's Proyecto BEST. Se reduce en un mes el tiempo para iniciar un ensayo clínico en España, with later coverage in 2017 and 2019. 2016.redaccionmedica.comRead: full textCited here
  30. Region Hovedstaden research portal. Screen failures and causes in inflammatory bowel disease randomised trials: a CRO analysis of 17 trials (Inflammatory Bowel Diseases). 2025.research.regionh.dkRead: abstractCited here
  31. Sathian B, et al. Impact of COVID-19 on clinical trials, tabulating Medidata release 5.0 of 18 May 2020. Nepal Journal of Epidemiology. 2020.ebi.ac.ukRead: full text
  32. Sertkaya A, et al. Phase 3 per-study costs by therapeutic area, from Medidata data. Clinical Trials. 2016.No link recordedRead: index onlyCited here
  33. Tata Memorial Centre. Screen failure in 15 randomised controlled trials (PubMed Central PMC9934872). 2023.pmc.ncbi.nlm.nih.govRead: full textCited here
  34. Trial Agents. CTIS EU Phase 2 immunology timelines and factors (238 trials).trialagents.comRead: full text
  35. Tufts Center for the Study of Drug Development. Pre-study visit to first patient in by site type, 5,296 sites in 105 trials. 2012.No link recordedRead: index onlyCited here
  36. Tufts Center for the Study of Drug Development. Press release of 15 January 2013 on site enrolment performance, as reproduced by Fierce Biotech, Outsourcing-Pharma, and RAPS. 2013.No link recordedRead: index onlyCited here
  37. Tufts Center for the Study of Drug Development, via GlobeNewswire. Press release on site identification and start-up cycle times, survey of 591 sponsors and CROs. 2018.The original link no longer worksRead: full textCited here
  38. UC San Diego, eScholarship. Screen failure across 269 oncology trials, 2013 to 2021. 2022.escholarship.orgRead: full textCited here
  39. Urbas S, Sherlock C, Metcalfe P (AstraZeneca). Meta-analysis of recruitment across 20 oncology trials (Biostatistics 2020; arXiv 1910.07965). 2020.arxiv.orgRead: full textAlso in chapter 9Cited here
  40. WCG Data Intelligence. Accelerating study activation: breaking down silos for start-up success (webinar slides). 2025.wcgclinical.comRead: full textCited here

Chapter 9 The forecasting model: how the sites-needed planner will work

  1. Anisimov VV. Using mixed Poisson models in patient recruitment in multicentre clinical trials (World Congress on Engineering, pp. 1046–1049). 2008.iaeng.orgRead: full text
  2. Anisimov VV. Statistical modeling of clinical trials (recruitment and randomization) (Communications in Statistics, Theory and Methods 40(19–20):3684–3699). 2011.eprints.gla.ac.ukRead: abstract
  3. Anisimov VV. Discussion paper on recruitment modelling in Contemporary Clinical Trials (title not recorded in the note; Glasgow eprint 137911). 2016.eprints.gla.ac.ukRead: full text
  4. Anisimov VV, Austin MD. Modeling restricted enrollment and optimal cost-efficient design in multicenter clinical trials (arXiv:2212.12930). 2022.arxiv.orgRead: full textCited here
  5. Anisimov VV, Mijoule G, Turchetta M, Savy N. Modelling and forecasting patient recruitment in multicentre clinical trials with patients' dropout (arXiv:2202.06779; title as recorded in the note). 2022.arxiv.orgRead: full text
  6. Bakhshi A. MSc thesis, University of Glasgow: negative binomial fits to per-centre recruitment totals in 18 completed trials (title as catalogued not recorded in the note). 2011.theses.gla.ac.ukRead: full textCited here
  7. Bakhshi A, Senn S, Phillips A. Some issues in predicting patient recruitment in multi-centre clinical trials (Statistics in Medicine 32(30):5458–5468). 2013.doi.orgRead: abstract
  8. Barnard KD, Dent L, Cook A. A systematic review of models to predict recruitment to multicentre clinical trials (BMC Medical Research Methodology 10:63). 2010.pmc.ncbi.nlm.nih.govRead: full text
  9. Bütikofer L, Haynes A. accrualPlot 1.0.10, R package manual (CRAN).cran.r-project.orgRead: index only
  10. Carter RE. Application of stochastic processes to participant recruitment in clinical trials (Controlled Clinical Trials 25(5):429–436). 2004.doi.orgRead: abstract
  11. Carter RE, Sonne SC, Brady KT. Practical considerations for estimating clinical trial accrual periods: application to a multi-center effectiveness study (BMC Medical Research Methodology 5:11). 2005.pmc.ncbi.nlm.nih.govRead: full textCited here
  12. CRAN contributors. fahb, R package manual: hierarchical Poisson accrual with log-normal site rates.cran.r-project.orgRead: index only
  13. Deng Y, Zhang X, Long Q. Bayesian modeling and prediction of accrual in multi-regional clinical trials (Statistical Methods in Medical Research 26(2):752–765). 2017.pmc.ncbi.nlm.nih.govRead: full text
  14. Gajewski BJ, Jiang Y, and contributors. accrual 1.4, R package source, accrual.n.inform.R (CRAN, GPL-2; paper Jiang et al., Trials 17:336, 2016). 2016.raw.githubusercontent.comRead: full text
  15. Gajewski BJ, Simon SD, Carlson SE. Predicting accrual in clinical trials with Bayesian posterior predictive distributions (Statistics in Medicine 27(13):2328–2340). 2008.doi.orgRead: index only
  16. Hickey GL, and colleagues. goldilocks 1.0.0, R package manual (CRAN, GPL-3).cran.r-project.orgRead: index only
  17. Jiang Y, Simon S, Mayo MS, Gajewski BJ. Modeling and validating Bayesian accrual models on clinical data and simulations using adaptive priors (Statistics in Medicine 34(4):613–629). 2015.pmc.ncbi.nlm.nih.govRead: full text
  18. JMP Statistical Discovery. JMP Clinical user guide: Patient Recruitment.jmp.comRead: full text
  19. Lan Y, Tang G, Heitjan DF. Statistical modeling and prediction of clinical trial recruitment (Statistics in Medicine 38(6):945–955). 2019.pmc.ncbi.nlm.nih.govRead: full text
  20. Liu J, Wick J, Jiang Y, Mayo M, Gajewski B. Bayesian accrual modeling and prediction in multicenter clinical trials with varying center activation times (Pharmaceutical Statistics 19(5):692–709). 2020.pmc.ncbi.nlm.nih.govRead: full text
  21. Lu K. eventPred 0.3.1, R package manual (CRAN).cran.r-project.orgRead: index only
  22. Merck. simtrial, R package (CRAN): piecewise-exponential enrolment generator.cran.r-project.orgRead: index only
  23. Mijoule G, Minois N, Anisimov VV, Savy N. Springer chapter modelling screening loss with centre-specific beta probabilities inside a cost model (DOI 10.1007/978-1-4939-2104-1_36; title not recorded in the note). 2014.eprints.gla.ac.ukRead: abstract
  24. Minois N, Savy S, Lauwers-Cances V, Andrieu S, Savy N. How to deal with the Poisson-gamma model to forecast patients' recruitment in clinical trials when there are pauses in recruitment dynamic? (Contemporary Clinical Trials Communications, PMC5936707). 2017.europepmc.orgRead: full text
  25. Mountain R, Sherlock C. Recruitment prediction for multi-centre clinical trials based on a hierarchical Poisson-gamma model: asymptotic analysis and improved intervals (Biometrics 78(2):636–648; arXiv:1912.09790). 2022.arxiv.orgRead: full textCited here
  26. Ninh A, Hunt, Nguyen. Estimation of patient recruitment using summary data aggregated across trials (INFORMS Journal on Computing 2024.0780; R package pgc, MIT licence). 2024.github.comRead: index only
  27. Saha D, Anisimov V, Fedorov V, Heiberger R. useR 2010 slides on GSK's R and RExcel recruitment package (title not recorded in the note). 2010.r-project.orgRead: full text
  28. Shipes VB, Meinzer C, Wolf BJ, Li H, Carpenter MJ, Kamel H, Martin RH. Designing a phase-III time-to-event clinical trial using a modified sample size formula and Poisson-Gamma model for subject accrual that accounts for the lag in site initiation using the PERT distribution (Statistics in Medicine 42(30):5694–5707). 2023.pmc.ncbi.nlm.nih.govRead: full textCited here
  29. Turchetta M, and colleagues. A time-dependent Poisson-Gamma model for recruitment forecasting in multicenter studies (Statistics in Medicine 42(23):4193–4206; arXiv:2301.03710). 2023.arxiv.orgRead: full text
  30. Urbas S. ct-recuitment-prediction: R code for interim recruitment prediction (MLE.R, BMA.R, data_sim.R, Delay_process). 2022.github.comRead: index only
  31. Zhang X, Long Q. Stochastic modeling and prediction for accrual in clinical trials (Statistics in Medicine 29(6):649–658). 2010.doi.orgRead: abstract
  32. Zhong Y, Xing Y, Yu Y, Wang J. Enrollment forecast for clinical trials at the portfolio planning phase based on site-level historical data (Pharmaceutical Statistics 23(2):151–167; arXiv:2301.01351; companion paper Yu et al., Therapeutic Innovation and Regulatory Science 58(1):42–52). 2024.arxiv.orgRead: full text

Review note 01 Quality tolerance limits: which trial-level parameters matter most

  1. ACRO. 2025 RBQM Landscape Summary Report (2024 data). June. 2025.acrohealth.org
  2. ACRO and TransCelerate. Acceptable Ranges for Clinical Trials: Insights from ICH E6(R3). Version 1.0, 11 February. 2025.acrohealth.org
  3. Akl EA, Briel M, You JJ, et al. Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review. BMJ. 2012;344:e2809. 2012.bmj.comAlso in review note 02Cited here
  4. Bhagat R, Bojarski L, Chevalier S, et al. Quality Tolerance Limits: Framework for Successful Implementation in Clinical Development. Ther Innov Regul Sci. 2021;55(2):251-261. doi:10.1007/s43441-020-00209-0. 2021.pmc.ncbi.nlm.nih.gov
  5. de Viron S, Blais F. Quality Tolerance Limits: Why Breaches Happen Early and How to Act Fast. Applied Clinical Trials, 9 March. 2026.appliedclinicaltrialsonline.com
  6. de Viron S, Young S. Quality Tolerance Limits: A Review of Industry Trends. Applied Clinical Trials, 2 March. 2023.appliedclinicaltrialsonline.com
  7. Fergusson D, Aaron SD, Guyatt G, Hébert P. Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. BMJ. 2002;325:652. 2002.pmc.ncbi.nlm.nih.gov
  8. Getz K, Smith Z, Jain A, Krauss R. Benchmarking Protocol Deviations and Their Variation by Major Disease Categories. Ther Innov Regul Sci. 2022;56(4):632-636. doi:10.1007/s43441-022-00401-4. 2022.pmc.ncbi.nlm.nih.gov
  9. ICH. Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). 2016.database.ich.org
  10. Little RJ, D'Agostino R, Cohen ML, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012;367:1355-1360. 2012.doi.org
  11. Makowski M, Bhagat R, Chevalier S, et al. Historical Benchmarks for Quality Tolerance Limits Parameters in Clinical Trials. Ther Innov Regul Sci. 2021;55(6):1265-1273. doi:10.1007/s43441-021-00335-3. 2021.pmc.ncbi.nlm.nih.govCited here
  12. Stansbury N, et al. Risk-Based Quality Management: A Case for Centralized Monitoring. Ther Innov Regul Sci. doi:10.1007/s43441-024-00719-1. 2024.pmc.ncbi.nlm.nih.gov
  13. TransCelerate BioPharma. Member Companies Using the QTL Framework Report Benefits (implementation experiences page; adoption figure from 2021). 2021.transceleratebiopharmainc.com
  14. US FDA. Bioresearch Monitoring (BIMO) Fiscal Year 2024 Metrics. 2024.fda.gov
  15. Walsh M, Srinathan SK, McAuley DF, et al. The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index. J Clin Epidemiol. 2014;67(6):622-628. 2014.doi.orgCited here
  16. Wolfs M, Bojarski L, Young S, et al. Quality Tolerance Limits' Place in the Quality Management System and Link to the Statistical Trial Design: Case Studies and Recommendations from Early Adopters. Ther Innov Regul Sci. 2023;57(4):839-848. doi:10.1007/s43441-023-00504-6. 2023.pmc.ncbi.nlm.nih.gov
  17. Yelland LN, et al. Prevalence and reporting of recruitment, randomisation and treatment errors in clinical trials: a systematic review. Clin Trials. 2018.doi.orgCited here

Review note 02 Operational KPIs that predict trial outcome

  1. A machine learning approach for recruitment prediction in clinical trial design. arXiv:2111.07407. 2021.arxiv.org
  2. Applied Clinical Trials article on whether to extrapolate site enrolment from past performance (Phesi analysis; vendor view, read via search summary only).appliedclinicaltrialsonline.com
  3. Getz K. Can recruitment and retention get any worse? Applied Clinical Trials, 1 December 2019. 2019.appliedclinicaltrialsonline.com
  4. Hoy K, Gerds A, Chan J, et al. First accrual within 70 days of opening predicts overall trial accrual success (work in progress poster). Case Comprehensive Cancer Center, AACI Clinical Research Innovation meeting. 2023.aaci-cancer.org
  5. Imperial College London Joint Research Office. NIHR benchmark: Performance in Initiating and Delivering clinical research (70-day benchmark).imperial.ac.uk
  6. Lamberti MJ, Wilkinson M, Harper B, Morgan C, Getz K. Assessing study start-up practices, performance, and perceptions among sponsors and contract research organizations. Therapeutic Innovation & Regulatory Science 2018;52(5):572–578. 2018.doi.org
  7. Site-specific factors associated with clinical trial recruitment efficiency in general practice settings: a comparative descriptive analysis. PubMed Central PMC9985191.ncbi.nlm.nih.gov
  8. Sullivan LB. MCC metric of the month: on-time site initiation. Applied Clinical Trials, 15 November. 2013.appliedclinicaltrialsonline.com
  9. Tang C, Sherman SI, Price M, et al. Clinical trial characteristics and barriers to participant accrual: the MD Anderson Cancer Center experience over 30 years. Clinical Cancer Research 2017;23(6):1414–1421. doi:10.1158/1078-0432.CCR-16-2439. 2017.pmc.ncbi.nlm.nih.govCited here
  10. TransCelerate BioPharma. Risk-based monitoring interactive guide: risk indicators and thresholds.transceleratebiopharmainc.com

Review note 03 What works when a recruitment or retention metric goes red

  1. Brueton VC, Tierney JF, Stenning S, et al. Strategies to improve retention in randomised trials: a Cochrane systematic review and meta-analysis. BMJ Open. 2014.doi.org
  2. Brunsdon et al. What are the most important unanswered research questions in trial retention? The PRioRiTy II study. Trials. 2019.doi.org
  3. Giguere AM, Labrecque M, Borduas F, Rouleau M. Effectiveness of monetary incentives to recruit family physicians as study subjects: a randomized controlled trial. BMC Research Notes. 2015.doi.org
  4. Jones R, Jones RO, McCowan C, et al. The external validity of published randomized controlled trials in primary care. BMC Family Practice 2009;10:5. 2009.doi.orgCited here
  5. Koog YH, et al. External Validity of Knee Osteoarthritis Clinical Trials: A Systematic Review. Archives of Rheumatology. 2015.doi.orgCited here
  6. Lewis R, Todd R, Newton M, et al. The implementation and utility of patient screening logs in a multicentre randomised controlled oncology trial. Trials. 2020.doi.orgCited here
  7. Miyata BL, Tafuto B, Jose N. Methods and perceptions of success for patient recruitment in decentralized clinical studies. Journal of Clinical and Translational Science. 2023.doi.org
  8. Parekh et al. Audit of screen failure in 15 randomised studies from a low and middle-income country. ecancermedicalscience. 2022.doi.orgCited here
  9. Parker A, Arundel C, Clark L, et al. Undertaking Studies Within A Trial to evaluate recruitment and retention strategies for randomised controlled trials: lessons learnt from the PROMETHEUS research programme. Health Technology Assessment 2024;28(2). 2024.doi.org
  10. Rogers A, De Paoli G, Subbarayan S, et al. A systematic review of methods used to conduct decentralised clinical trials. British Journal of Clinical Pharmacology. 2022.doi.org
  11. Treweek S, et al. Methods to improve recruitment to randomised controlled trials: Cochrane systematic review and meta-analysis. BMJ Open 2013;3:e002360. 2013.bmjopen.bmj.com
  12. Tufts Center for the Study of Drug Development. Protocol amendments improve elements of clinical trial feasibility, but at high economic and cycle time cost (press release, 14 January 2016, via BioSpace). 2016.biospace.com
  13. Worldwide Clinical Trials. Unique 4-step approach limits high screen failure in Alzheimer's disease research, part 1 (industry blog, 2017). 2017.worldwide.comCited here

Added while building the site

  1. BOE. Real Decreto 463/2020, de 14 de marzo, por el que se declara el estado de alarma para la gestión de la situación de crisis sanitaria ocasionada por el COVID-19. Boletín Oficial del Estado 67. 2020.boe.esCited here
  2. Gazzetta Ufficiale. Decreto-legge 23 febbraio 2020, n. 6: misure urgenti in materia di contenimento e gestione dell’emergenza epidemiologica da COVID-19. Gazzetta Ufficiale della Repubblica Italiana, Serie Generale 45. 2020.gazzettaufficiale.itCited here
  3. Khan MS, Jamil A, Shakoor M, et al. Patient Enrollment for Cardiovascular Clinical Trials in the United States. JAMA Cardiology 10(3):298-300. 2025.doi.orgCited here
  4. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine 381:1995-2008. 2019.doi.orgCited here
  5. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine 383:1413-1424. 2020.doi.orgCited here
  6. Patel VR, Liu M, Jena AB. Clinical Trials Affected by Research Grant Terminations at the National Institutes of Health. JAMA Internal Medicine. 2025.doi.orgCited here
  7. Prime Minister’s Office. Prime Minister’s address to the nation on coronavirus: 23 March 2020. GOV.UK. 2020.gov.ukCited here
  8. Spiegelhalter DJ. Funnel plots for comparing institutional performance. Statistics in Medicine 24(8):1185-1202. 2005.doi.orgCited here
  9. The Lancet. India’s COVID-19 emergency. The Lancet 397(10286):1683. 2021.doi.orgCited here
  10. Tian H, Liu Y, Li Y, et al. An investigation of transmission control measures during the first 50 days of the COVID-19 epidemic in China. Science 368(6491):638-642. 2020.doi.orgCited here
  11. TransCelerate BioPharma. Risk Assessment and Categorization Tool (RACT), in The TransCelerate Model Approach. Risk-based monitoring interactive guide. 2013.transceleratebiopharmainc.comCited here
  12. UN Special Advisers. Joint statement by the UN Special Advisers on the Prevention of Genocide and on the Responsibility to Protect on the situation in northeast Syria. United Nations press release, New York, 15 October 2019. 2019.globalr2p.orgCited here
  13. UNHCR. Ukraine refugee situation: operational data portal. UNHCR. 2022.data.unhcr.orgCited here
  14. US Congress. Food and Drug Omnibus Reform Act of 2022 (FDORA), in the Consolidated Appropriations Act, 2023. Public Law 117-328, Division FF, Title III. 2022.govinfo.govCited here